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CHAPTER 1 
INTRODUCTION 
INTRODUCTION 
The term "fungal infection" signifies the sum of 
t)io 1 oq 1 ca 1 procesBes which tai<e p 1 ace in the macro organi sm 
LI. p o n t h e p e n e t. r a t i o n o f pathogenic: -f u n g u s (m i c: r o - o r g a n i s m) 
into it, independent of whether the penetration will entail 
the development of an obvious or latent disease or whetht^r 
the macro-organism will only become a temporary carrier of 
the causative agent. This whole series of event constitutes 
the infectious process and one of the extreme degrees of 
manifestation of infection process is designated 
as infectious disease (1)„ Fungal infections(2) can be 
classified into: 
:i. ) S u p e r f i c i a 1 f u n gal infect i o n s, 
i i ) C u t a n e a u s f i.t n g a 1 infections, 
i 1 i ) S 1.1. b c u t a n e o u s f u n g a 1 i n f e c t i o n s a ri d 
i V) S y s t e? m i c: f u n gal i ri f e c t i o n s 
Superficial Fungal Infections 
These include diseases in which a cellular response of 
the hcjst IS lacking- Invasion of fungi occurs only on the 
outer layers of the skin e.g. Tinea versicolor. Tinea 
nigra, White piedra, E^lack piedra etc. 
Cutaneous Fungal Infections 
Cutaneous f unga 1 i nf ect i ons are conimon .i. ri trie 
keratini;:ed tissue of the host, like hair and nails. Fungi 
invades only epidermis and its appendages. The lesion of 
1 
in-fec:ted sk i n is roughly circ.u 1 ar ar"id u.sua 11 y e;•;pand in a 1 i 
directions. Some e>; amp lea o-f infectious- cutaneous -fungi are 
Tinea capitis, Tinea cprporis, Tinea cruris and Tinea pedis. 
Subcutaneous Fungal Infections 
Such mycotic infections are usually common in the inner 
layev- (dermis) of the skin. The infection is, initiated by the; 
penetration of fungi associated with contaminated splinte^rs, 
thorns or soil into the skin. Invasion of fungi may also 
occur by direct implantation of soil fungus into the affected 
areas of the skin. Once established, these infections tend 
to e>;tend to bone and lymphatic system. 
Systemic Fungal Infection 
These are most common and life threaiteninq amongst 
i mmunoccmrpromi Bed patients. The infection is initiated by 
the d i r ec:;t i nha 1 at i on of f ur"iqa 1 s|::>ores i n the 1 urig w11fi 
subsequent hemaitogenous spread to other viscera and the 
central nervous system. The increased incidence of systemic: 
fungal infection that has bieen noticed during the last 
decade can be attritautesd to a number of factors, sucn 
as treatmient with broad spectrum antitaioticB, 
c o r t i c D s t e r o i d s>, a n t i n e o p 1 a s t i c d r u g s, ope n s u i- q e r y, a r i (:i 
other c o n d i t i o n s that le-!£id to impaired host. natural 
resistance (3--7) . 
C o r i s i d e r a b 1 e;: e f• f o r t s h a v e b e e n fn a d e i n t r e a t i n a 
f Ling a 1 i n f e c 11 o n s ta t..i t s u e c e s s f u 1 11- e a't, m e n t of s y s 1: e m i c f u ri q a i 
infections- has remained problematic because the therapeutic 
armoament€-(rlum has been limited in v<Ariety and efficacy. 
Most of these? infections are caused by species of Aspergilius, 
Candida, Blastomyces, Cryptococcus, Histoplasma especially 
in the immunocomprofru sed and neutropenic host (8-10). Among 
these, Candida and Aspergillus species are most. common 
p a t h o g e n s. 0 u r w o r k m a, i n 1 y c o n c e r n s s y s t e m i c A s p e r g i I 1 o s i s 
and hence will be taken up in slightly more dc-jtail. 
Candida Albicans 
The^ se^  are opportunistic pathogens giving rise to iocai 
1 n-f 1 amat i on under a wide variety of conditions. The 
inflammatory reaction is normally mild and superficial with 
p o 1 y m o r p ri o n Li c 1 e a r e ;•; u d a t e b u t s y s t e m i c i n v a s i o n m a y o c c u r i r i 
drug addicts and patients on immunosuppjressi ve or cytotDxic 
therapy. The common sites of the infection ans mouth, 
intestine, lower respiratory tract, and vagina (11), The 
infection of the mucosa is known as "thrush",, The commonest 
Candida infection is vaginitis or vaginal thrush. F-'regnant 
vjomen >are very susceptible to Candida infection. There is 
an acidic whitish discharge and microscopically some pus 
cell s a n d /n a n y y e a s t s, in c 1 u d i n g p s e u d o m y c e 1 i a 1 f o i- m s, are 
V1 s i b 1 e . 
Aspergi11osis 
A s frj e r g i 1 1 o s i s i s a g r- a n u 1 o m a t o u s, n e c r o t i s i n g a n d 
cavitory disease of the lungs, often with hematogenous spr&^ad 
''12)- It is one of the most common airborne systemic fungal 
infection which can be fatal for immunodebi1itated patients 
such as those suffering from AIDS, ca\ncer, tutaercu'l usi s etc. 
The causative agent is the most commonly isolated species 
Asperqillus fumiqatus. Species of aspergillus are ubiquitous 
m nature and particularly abundant in soil, farm houses, 
barns,, gram dust and decaying vegetation. The conidiophore 
'•'•^' Asperqi 1 1 us f umi gat us is a single stalk with large 
t£-:'rm:i. nal vesicles contauning many sterigmata which be?ar long 
chains of conidia. The spores are small in diameter (2.5-3 
urn) and are readily inhaled. The infection is initiated by 
direct inhalation of fungal spore in the lungs from where it 
may disseminate to different parts of the body. Asperqi11 us 
f umi gat us invader-. the lung parenchyma in immunocompromised 
patients and can colonise in pre-e>; i sti ng or healed 
t u b e r cu1ou s p u1mon ar y cavities (13). T h e t h r e a t ass um es 
alarming proportions in individuals who have undergone renai 
transplantation or have haematological neoplasia or chronic 
g r a n u 1 o in a t o u s d i s e a s e. In addition A s p e r gill u s e i" 11 e r s-
through the respiratory tract, it subsequently invades blood 
vessels and causes thrombosis, and infarcts,, causing 
manifestation of the disease in like brain, liver, spleen, 
k i d n e y o r o t h e r organs. Categories o f 1 u n g i n f e c; t i o n c. a u. s e o 
by aspergillus are divided according to distinct clinical 
syndromes. 
1 " Hypersensi t;i yi ty lung di seases; E;•;tri nsic Asthma, 
Extrinsic Allergic Alveolitis, Allergic bronchopulmonary 
Asperqi11osi s. 
2" Non-- i f ivas 1 ye in-f e c t i can: Pu 1 monar• y a s p e r g i i 1 ofcia, 
Suppre<3si ve Bronch i t. i s . 
•-•'. Invasi ve i n f ect i on; Chronic necrotizing. Acute 
nscrotiz i ng. 
The clinical mani f e^stati ons are usually overlapping 
and the aspergillus lung infections c.€ui not always be place)?d 
unde?r diffEn"ent categories. Persons suffering froiTi 
aspergi llama mary develop bronchopulmonary Aspergillosis,, 
S1 m i 1 ar 1 y pn eumon i a men i f es;t s AS £ieper• g i 11 oma. 1"her ap y w11 ri 
c o 1 - 1.1 c o s t e r' o ids f o r i n v a s i v e a s p e r g i 1 1 o s i s c a n i, m p a 11" t h e 
ac;: c uiTIU 1 a 11 an of p h a g o c y t es at i n f 1 amat or y s i t e s , b ac t, er i c: i d a i. 
and candidacidal activity of monocytes, cell mediated 
immunity (14-16) and also the natural resistance. The 
i. r,c!''easi ng i nc i dence of asper g i 11 osi s i n chr ori i c 
granulaamatous patients impairs phagocytic action against 
aspergilli. Until 1970 it was not clear, whether phagocytes 
can kill spores or mycelial of A_^  f umi gat us in vitro but the 
evidence was there that polymorphonuclear granulocytes (PMN) 
cun damage the hyphae (17). 
It has bE?en shown that natural immunity to resting 
spor-es of A_.__ f umi gat us is independent of PMN, T lymphocytes 
and humoral immunity but the3 mononucleaxr phagocytes, and 
neutrophils can kill the fungus in its conidial stage very 
efficiently. Andreas Schaffner eJL^  al (1982) demonstrated, 
(IS) by iji vi yo as well as i_n vitro studies that spores of 
A.;- f umi gat us are readily ingested by macrophages. 
Polyene Antibiotics 
Si nc;:e the di BC:OVer y ot Ny51.at i n, 111 e -f i r st memt:)er ot 
this class of compounds, ijy Ha2'~.:, and Brown in 1950, (19), 
many other polyene antibiotics haive been described. I'lost of 
thesf-- are produced by soil acti onomyct^tes 0+ the genus 
StrciJtoiTiyces. 
At. present more than 200 polyenes are known and o-f 
these, 40 hatve known structures (20) „ Among the large livst ot 
p o 1 y e r"i e a n t i b i c:) 1 1 c s t h a t h a v e b e e; n 1 s o 1 a t e d a r 1 d ci e^  s c ri b e a , 
some Bre most effective antifungal agents but the problem 
associated with solubility, stability, absorption and 
toMicity limits their maximal exploitation in clinical 
medicine- Polyenes can fcse divided into three main 
categories on the basis of their structure-
1, Polyenes containing sugar residue 
2 „ (••' o l y e n e s w i t li o u t s 1.1 gar i" e s i d u e 
3. Ar omat1c polyenes 
Polyenes with sugar moiety are effective antifugal 
agents. Amp-B and nystatin are important members of this 
group. Amp--B forms small pores in the membrane ranging from 
o 
8--10 A in diameter (21--23). The best example of polyenes 
wnicn an not have sugar moiety is filipin. The pore formed 
these polyenes are bigger in diameter for e.g. filipin forms 
o 
a pore of 150 250 A in di ameter (24-25) . Aromatic F-'olyenes 
are very promising antifungal agents. The activity of these 
aromatic polyenes is higher against, yeast cells as comparec 
to non aromatic polyenes. The distinctive feature of this 
class of polyenes :i s that, they contarin a p-aminDphenyl or p 
W-methyi amxnophenyl group In their structure e.g., hamycm, 
perimycin A, candi ci di n D., pairticin A,, vac i din A. 
Physico chemical properties of Polyene antibiotics 
E',1 emental analysis of polyene antibiotics shows that 
t h e y c. o n t a i ri c a r b o n , hi y d r o g e n , o ;•; y g en arid in s o m e i n s t a i • J C B B 
n it r oq e n i26) . Jhe major character i st i c f eatur 
polyene antibiotics is the presence o-f the large macrolicie 
ring in its structure. Pcjlyenes are? classi-fied according to 
the number of double bonds in the principal chromophore ^^:, 
either trienes., tetraenes, pentaenes, hexaenes or heptaenes., 
None D+ the trinees contain carbohydrate units but Hiany 
tetraenes contain the amino sugar ,, mycosami ne« The macrolide 
ri?ig contains three to eight conjugated double bonds with one 
sugar moiety linked through a glycos:i.dic linkage,, The ring 
size Var i e5ii from 1 2~ 14 tc:i 35••- 37 car"taon atoms, Macr• o 1 i cie 
confer-s a characteristic peak on infrared spectra of these 
polyenes,, In 1971, Ganis et^  al_ (27) showed tav X-ray 
crystal 1 ographi c studies the\t all the double? bonds of Amp B 
were in trans configuration. The polyene antibiotic has a 
large number of hydroxy! groups usually distributed on the 
ma c r o 1 i d e r i n g on a 11 er n at e c. ar b on at oms. Th e n u(lib e?r of 
hydroxyl group varies from 6-14. The presence of polar 
n y a r o x V i g r o u p s and m u l t i p l e hydrc jphc j ta ic d c j u b l e b o n d s m t h e 
m a c r o l i d e o f p o l y e n e s c o n f e r s t h e a d d i t i o n a l p r o p e r t y o f 
11-i e i 1- i::) e i n g a m p hi i p a t i-i i c:, T hi i s amp h i p a t |-i i c f e a t u r e o f a o 1 y e n e 
antibiotic plays a major role in its interaction wjth 
bi omol ecLil es in vs^rious biological syst.ems. The hydrophobic 
and hydrophi11ic components reside opposite each other in the 
macrolide ring. The carbohydrate in all polyenes was found 
to be? mycDsamme. The structure was established in 1961 by 
Von Saltze et„al. (28) when they chemically synthesized the 
mycosamine molecule. This is a 3 amino analogue of D 
rhamnose? or 6~deo>;y--D mannos-e. The - pyranose ring form of 
mycoasamine is more stable than the - -furanose r-inq 
structure. 
The most distinctive physical characteristic of polyene 
a n 11 i:.-) i o t i c: s i s t hi e U V a b s o r p t i o n spec: 11- u m. T h e a b s o r p 11 o n 
spectra ranges from 2EI0~405 nm. Oroshnik and ilebane ( 1V63) 
hypothesized (29) that the characteristic absorption spectra 
of polyenes is due to the conjugated double? bond system,, 
The presence of several distinct classes of chromophores 
i„e. tetraenes, pentaenes, hexaenes and heptaenes have Deei! 
indicated from the analysis of different U'v absorption 
spectra. 
Due to the amphipathic nature of the? polyene 
antibiotics they show limited solubility in both water an.a 
in organic solvents such as alcohols, esters or ethers. 
F-'o 1 y en es f or m suspen s i on of micelles rather 111 an t r ue 
solutions in aqueous solvents- F-'olyenes may be dissolved m 
very polar organic solvents, such as di methyl sui pho;; i de 
(DMSO) or dimethyl formamide (DMFO). Solutions of antibiotics 
8 
in DMFQ or DMSO are stable if they are protected from light 
and oxygen to which they are very susceptible. 
P o 1 y e r'I e s e;•; e r t i n h i b i t i or-i a g a i n s t m a n y B p e c i e s o f f o. n g i 
such as yeasts (e.g. Candida), dimorphic fungi (e.g. Histo-
plaema), dermatophytes (e.g. Tr i chophytcsn) and moulds (e.g. 
Aspergillus) (30). Interestingly they have no activity 
against intact bacteria. 
F-'olyene?s are also to>;ic to protozoa many of whicn are 
of medical importance such as Entamcjeba, Trypanosomes and 
Leishmania species. Polyenes alter membrane permeability 
d u. e t o w h 1 c h t in e r • e is a 1 o s s o f i n 11'- a c ell u 1 a r c o n s 111 u e n t s 
leading to the lysis of the cells. It has, be?en seen that as 
the number of double bonds increase in the structure, 
the polyenes become more toxic. Kitahara et.al. 1976 stuciec 
various factors which effect the inhibition of polyenes. The 
f a c:: t o r 'J:-; W h i c h m a y a f f e c t t h e m i n i /it u m i n h i t:; i t o r y p c:) t e n c: y w e r e 
inoculum size, temperature, duration of incubevtion and medium 
composition (31)„ The presence of serum reduces the activity 
of the polyenes. 
Mechanism of action of Polyene antibiotics 
In the early i960"s, several laboratories reported tfiar 
polyene antibiotics can increase the cell membrane 
permeability of various organisms. The increase in ceil 
m e m t:i i- a n e p e r m e a b i 1 i t y r" e s u 11 s i n t h e 1 e a k a g e o f s e v e r a 1 v 11 a 1 
metabolites vis K , Na , H ions. leading eventually to 
cell lysis and death. Kinsky et.. al..,, (32--33) observed that 
polyenes caused a rapid decrease in the dry weight of 
myceliai material, fcjl lowed by leakage of aminaacxds, sugars 
and o t h e r m e t a h o 1 i t e s i n t o c u 11 u r e m e d i a. T h is; e t f e c t w a s 
e V1 d e n t e v e n a t v e r y low c o n c e n t r- a t i o n s < 1 u M) CD f t i-i e p o 1 y e n e. 
The et-fect was speci-fic -for polyene antibiotics but other 
metabolic inhibitors or non-polyene type of agents were 
ineffective (32 33). These studies indicate that polyene 
antibiotics act ai: the membrane level. Since the plasma 
(n e I(i b !'"• a n e i <B r e s p on s i b 1 e f o r ma i ri t en a n c e o t c ell m e (ifitj r a n e 
permeability, it is logical to think that plasma membrane is 
t r 1 e s 11e o f ac: t i on of polyenes. 
As stated earlier, intact bacteria aire not sensitive to 
polyenes and hence unaffected by them. On the contrary, 
fungi, leishmania species and human red blood ceils are 
susceptible. Bacteria do not have sterol in their membrane 
whereas fungi/mammal i an/protozoiii membranes do have it. 
These observations led various scientists to propose a 
hypothesis that polyenes interect with the membrane sterols 
which are prt^sent in eukaryotic cells but are not found m 
bacterial cell walls or membranes. In 1960, Lampen etj^.al._„ (3.4) 
ob se!'•• ved t hi a t add i t i on of st er a 1 t o an agueous so 1 u t ion c:)f 
polye-?ne decreased the atasorbance of the antibiotic and there 
V'jai.s an increjause in absorbance? wh6?n the antibiotic was taken 
in an organic solvent. Such a change in absorbance value is a 
clear indication of the antibiotics interaction with sterol. 
Regarding the sterol selectivity of polyenes, it has been 
10 
observed that. erqoste;rol is preferred over choiesterol 
('5 5) „ F-' u n g a 1 c e 1 Is do h a v e e r g o s t e r- o i w h e r e a s i n m a m rn a 1 :i. a n 
cells ergosteroi is replaced by cholesterol and thus polyene 
antioiotic preferentially lyse fungus cells. Several 
attempts have been made to corelate the resistance strains of 
various fungi such as S^ ,, Cerevi sae, Candida albicans in the 
light of sterol conterst specificity. Mc^ lzahri and Woods 
(1972) reported alteration in the sterol content in nystatin 
resistance S^ .. Cerevi sae cells (36). It has been suggested 
that zymosterol may have replaced ergosteroi heres. Ttie ijj 
vi tro analysis of polyene? resistisnt yeast mutant reve^als a 
lower or ncvi-gi i gi bl e ergosteroi content than the corresponai ng 
wild type (37--39) although the total sterol content may 
increase (40). It should be mentioned here that the formation 
of methylated sterol has been report€?d in the resistance 
strain of S.»_. cerevi sae (105). Thus it appears that 
iTi o d i f i c a t i o n o f s t e r o 1 m a y d e c r e ^t s e t hi e a b r o g a t e b i n d i n a 
affinity for polyene to sterol, rendering the fungus 
resistant. F^eports BTB also available m which it has beeri 
shown that resistance is not only limited to sterol content 
but lipid composition may also play an important role (3E3). 
The specific enrichment of phosphatidylcholine, 
phospltatidylserine, phosphati dyl ethanol ami ne in the S_^  
cerevisi ae cells can offer protection from the polyene 
a n t i b i CD t i c ac. 11 o n ( 41 - 4 3) . 
There ars a number of models.-, which have been used to 
study the mechanism of action of polyene antibiotic, These 
11 
mDde 1 5 (44-47) i nc 1 ude Acholepl asfria\ 1 ai dl awai cells, p 1 ar-iar 
bilayers and liposomes ( SUV, LUV and M L V ) . 
Acholeplasma 1ai dlawai cell serve as a suitable model 
system because of the fact that they do not have any sterol 
on their membrane taut can incorporate sterol when grown m a 
sterol rich media. Fill pin and Amp-Ei could inhibit the 
growth o-f A._ 1 aidl awai cells only when they are grown iii a 
media containing sterol. A large number of groups reporter 
(48-49) that sterol added to the medium of (i^.. 1 aidlawai 
(having incorporated sterol in the membrane) could protect 
the cells from the antibiotic (50-52:). It has been obse?rved 
that ergosterol containg .^u.. 1 ai dl awai cells are much more 
sensit-ive to Amp-B and its ester derivative than are the 
c hi o 1 e •;:; t er o 1 c; o n t a i n :i. n g cells. Studies w i t hi liposomal m o d e 1 
membrane have be^en done to understand the sterol specificity 
of polyenes but unfortunately result??, Ar& not so clear cut and 
sometimes appear to be controversial. The selectivity could 
be demonstrated using MLV as model me^mbrane and Amp--B as the 
antibiotic (5:3). When E5UV was used as model membrane, such 
selectivity for sterol could not be demonstrated in the case 
of Amp-B (54) or nystatin (55). It is thus apparent that such 
controversies may root from the selection of a particular 
(Tiocj E? 1 ineiTib r• arIe o!- t he? methodo 1 og i es used for d emon st r a11 ng 
the selectivity. In fact, it has been observed that m 
SlJVs where Amp--B is directly incorporated,, such specificity 
for sterol is poorly expressed as studied by cation/proton 
exchange method (56) „ But the transfer cA- Amp B from DPF-'C 
vesicles to another SUVs could express such speciticity. Thus 
selection o-f a particular type of model membrane and 
p a r a ITI e t. e f" S use d t o study s e 1 e c t i v i t y a n d per m e a b i 1 i t y m s y 
pose prob 1 ems to el uci date the present concGpt r ega;-cji ng t'ne 
mechanism of action of polyene antibiotic. It should be notea 
he; re that the present concept regarding the mode of 
action of polyene antibiotic is that it interacts 
pre^f ereti al ly with the fungal sterol, ergosterol and forms 
transmembrane channel through which the essential components 
of the cell leak causing cell death. The conclusion has been 
arrived from physical studies such as spectrophotometric, 
CD and measurement of cation permeability by the exchange 
method using various mcidel membranes such as planar 
membranes, HLV and SUV. A limited amount of work in the !;:,ame 
direction has been done with LUV as the model. At this 
point, it should be emphasise^d that one should take care 
in choosing a particular model membranes which could mimic the 
f ungus/F<EiC membrane, Bolard et. gil . (57) have pointed out that 
SUV, bec.ause of thie strong curvatui"e of the bi 1 ayer-s cou 1 d 
not fc)e used as i dea 1 model f or i nter ac:t i ori st uc:i i e?s. T |-"iey 
also mention6?d that although MLVs have large diameter but 
because of broad light scattering, there is an impairment in 
o p 11 c: a 1 m e a s u i'" e m e n t - I n a d d i t i o n t o t h a t, i n 111.. V s t h e 
internal leaflets &re not directly accessible to t.he 
antibiotic which may raise a question regarding the validity 
of quantitative mE^asurements (20). In a recent paper, 
Bolard-'s group (58) suggested that LUVs could be ideal for 
studies of such interactions and studied extensivelv the 
binding o+ Amp--B and filipin with LUVs and its after effect 
such as permeability changes to gain an insight into the 
mechanism of polyene antibiotic action. Applying CD 
techniques, they showed that the Amp-B interaction with 
LUV IB different f^ rom that with SUV. Furthermore they 
obtained completely di-f-ferent spectra for Amp-B interaction 
with cholesterol and ergosterol containing LUVs, 
i- e s p e (;  1: i v e 1 y „ S u c h s p e c i f i c i t y h a s n o t b e e n o b s e r v e d w 11 n 
SUvs (59). The interaction oi -filipin with LUV occurs at much 
higher concentration of antibiotic (ejqual or higher than 10 
uli) than that o-f Amp-B (around 1 uM) (58) . The (DD spectra for 
filipin binding to LUVs remains unaltered irrespective of 
the nature of the sterol (58). Moreover f i l i p m binds to 
sterol free liposomes (without sterol in liposomes),, Binding 
of filipin with LUVs is observed which in turn indicates tne 
binding of filipin with phospholipids. Thus in liposomes 
with sterol, there is competition between sterol ana 
phospholipid of liposomes for binding with filipin. 
Existence of such type of phosphol i pi d-Amphoter i ci n B comple;-; 
in EF-'C LUVs is however not possible to demonstrate (58). 
W|-"i i 1 e add r essi ng t!-i e? Amp•-B i n duc ed pe?r meab i 1 i t y of LUV, 
Bolard's group, using EP(-;/Chol LUVs observed the cation 
+•2 - 7 
leakage (Ca ) at Amp-B concentrations a\5 low as 3 X 10 M; 
90% leakage was observed at 10 sec. When sterol is 
i ncorpor atefd into liposomes, similar events occurecl, but at 
an Amp-B concentration almcjst 10 times lesser (5Ei) . The 
incubation of Amp B at a concentration higher than 1 uM 
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with ergosterol--containing EPC LUV at 30 C for long periods 
le?ad3 to the appearance of ionic channels with enlarged 
diameter which enable the' release of larger rnoleculeB like 
glucose (61). 
Thus the importance of physical studies on the 
inter<sction of polyenes with LUVs as mode?! membrane could 
explain sterol selectivity of the antibiotic and also the 
formation of ionic channels in sterol containing membranes 
which may form the basis of the mechanism of antibiotic 
a c: t i or I. 
Studiers with varicius model m€-;mbranes indicate the 
formation of ionic channels after the polyene antibiotic 
binds to membrane sterol. In this, attempts have been made 
t.o elaborate the nature of pores and the possible intei- action 
of the antibiotic with membrane in such pores. 
The hydrophobic channel of a pore formed after polyene 
o 
binding to membrane has a radius of 5 A (21--23) . 
Interaction between polyene antibiotics and sterol have some 
common charactersti c features v i ) Within these comple;-;es the 
interaction is mainly hydrophobic (ii). Polyene antibiotics 
can make compleises only with membrane sterols having 3B~0H 
group, a planar ring system and hydrophobic side chain at CI 7 
(62) (iii). The number of cholesterol molecules per mole of 
polyene antibiotics in the comple;-; is of the same order,, 
Despite these common characteristic -features, there ars! 
remarkable differences among the various polyene ancibiotics 
i r-I i I'lduc i ng memtar anB permeabi 1 i t y. The -f i 1 i pi n -- cho.1 es te r oI 
o 
comple;-; forms an aggregate of 150--250 A in diameter withm 
the membrane (24-25) and leads to release of cytoplasmic 
c: o m p o n e n t s „ T h e c o m p i e ;•; f c:i r m e d b y c: hi o 1 e s t e r o 1 w 11 h 
Amphoter 1 ci n--B, Nystatin functions as an aqueous channel 
traversing the membrsine while the pimaricin cholesterol 
comple;-; does not alter permeability of A,_ 1 ai dl awi i cells and 
liposomes (xb3--64) . Dekruiyff, et. BJ^. (1974) demonstr att-sd 
1 m p o r t a n t f e a t u r e s o f A m p h o t e r i c i n - B, c h o 1 e s t e r o 1 a n d 
distearyl lecithin complex by space filling models (65). The 
length of the double bond systtem of Amphoteri c i n--B is equal 
to the length of the cholesterol molecule. The carbo>;yl group 
and the mycosamine residue are: located at one side of the 
molecule, making it amphipathic. The only hydroxyl group of 
the i'-ing system not aligned with the other hydroKyl group is 
surrounded by 3 methyl groups. The length of lecithin 
m o 1 e c u 1 e i s a 1 (ri o s t s a m e a s t hi e 1 en g t h of t h e Am f j h o I: e r i c: ;i. i-i - B 
molecule as measured from charged phosphate group to terminal 
methyl group. The charged group of amphoter i ci n--B and 
hydra;-!yl group of cholesterol is located on the same side of 
the complex. This is a characteristic feature of Amp B 
cholesterol complex m which the cholesterol molecule 
complements the ring of the Amp--B molecule. The Amp B (A), 
cholesterol (C) complex model has shown that (A C) can form a 
half pore through the lipid bilayer. Two such half pores on 
either side of the lipid biiayer 3.re necessary for complete 
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por e f ormat i on , Trie hyd r o;•; y i gr• oi..ip o + Amp--B ma.y be i rivoI ved 
1 n a n c h o ring the two hi a 1 -f p o r e s a n d s t a b i 1 i T. i rig t. h e 
c o f 1 (;:l i..i. <;;: t i n g c ri a n n e J. . 
In 1974 Andreoli et. al . gave a tentative hvpothesis; 
based on experimental data -for Amp-B cholesterol pore (44),, 
Schematic representation of this hypothesis shows C 1- C 13 
and C 20 -• C~ s G^  g m e ri t o i A m p -- B p i c t n r e d ai s od 11k e 
o 
afra.y^ 20-24 A long. The (I;- 15 hydro;•; y 1 gr ot.ipi, 
cartao;;yl group, and C-19 mycosamine group are at the end of 
the rod with these hydrophiliic groups located at the water 
bilayer interface, the rod being situated in the membrane 
i ri t. e r i c:) i-~, p a r a 1 1 e 1 t C3 t hi e h y d r o p h o b i c. c n a i n s o f t. h e 
phospholipid,, the planar cyclopentano phenanthrene skeleton 
and the C-i7 acyl residue of cholesterol. According to this 
hypothesis two types of hydrogen bondings are involved. One; 
is the hydrogen bonding between 3-OH proton of cholesterol 
a i-i d f: - 16 c o r ta o ;•; y 1 g r o u p o f A m p - B, a n d t hi e s e c o n d i n v o 1 v e d 
between the 3-DH oxygen of cholesterol and the C 17 hydroKvl 
p 1" c:i t • -! n o f A m p E-f. 
Amphotericin-B 
Anip'-Fi IS the major drug of choice for the treatment of 
aspergillosis,, Amp B is a polyene antibiotic derived from a 
strain of 3tj;:.e2.tonr;fX;^ s nodosus (66). It is a low molecular 
weight compound (Mol Wt 924,1), The molecule is roughly 
o 
about 24 A long. The gl ycosi di cal 1 y linked ammosuqar 
mycosamine and carboxyl side chain give the compound its 
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amphoteric nature. It is insoluble m water and shows 
greatest anti-fungal activity between pH 4.2 and 6,. 5, The 
d r u g :i B a v a i 1 a b :L e c o m m e? r c i a 11 y a s a t (;:i p i c a 1 c r e a m, o r • a i 
suspefiBi on, tablets and in powder form suspended 
in deo;; v'chol ate. The commercial name of the latter form i s 
fungizone which contadns; 50 mg Amp-B and 41 mg of sodium 
d e o ;•; •/ c |-i o 1 a t e w i t)-, 2 5 . 2 m g s o d i LI m p h o s p t~i a t e a s b u f f- e i- •. 
The deoxycholate form i is widely used intravenously to 
treat several fungal infections including Aspergillosis. As 
stated earlier the antifungal activity of Amp-B lies in its 
pref ererit i al binding to ergosterol , a fungal sterol founci in 
11T e m e m b r a n e s, f o r m i n g t r a n s rn e m b r a n e c h a n n e 1 s o f 
o 
approximately 10 A in diameter. This causes the release of 
vital metabolites from the fungal cell and ultimately its 
lysis. However, the drug can also interact with cholesterol 
f o u n a 1 n m e m b i-• a n e s o f (Ti a m in a 1 i a n c e 11 s (e s p e c i a 11 y r • e d ta 1 o a a 
c e l l s ) l e a d i n g t o a s i m i l a r e f f e c t . T h i s m a k e s i t h i g h l y 
to;•; 1 c and th ius h a s s e v e r G 1 y i - e a t r i c t e d t ITe ma;•; i mai 
exploitation of Amp--B as a therapeutic agent in clinical 
m e d i c i n e. - A m p ••- B a 1 so a c c u m u 1 a t e s in t h e cells of V:. i d n e y a ri d 
produces nephrotoxicity (6S), which causes an unavoidable 
side effect of Amp-B leading to rcenal dysfunci:ion and is 
manifested as azotaema, renal tubular acidosis along witn 
loss of potassium. Several other adverse reactions of Amp B 
ars now well established. These include anorexia, nausea,, 
f eve!• •,, i-Ieadache and vomi t i ng „ 
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LIPOSOME 
PhoBphol ipid vesicles (liposomes) were •first described 
two decades ago by Bangham et. al . (69) . It has been shov-Mn 
that phospholipids spontanesousl y form closed structures when 
hyd rated i n aqu.eous so 1 ut i on. Jhe^a vesicles, composed o + orie 
o r i-fi o r e p hi o B p h o lipid b i 1 a y e r m e m bra n e s, c a n c a i-  r y d r LI g s 
either in the aqueous phase or in the lipid phase depending 
on the nature of the drug. Liposomes vary in charge 
(positive, negative), size (MLV-'-si ze range CI--5 urn BiJV 
0.02 0.05 um, LUv size is about 0.06 urn) depending on the 
me?thod of preparation and the lipids used. A large number of 
g e ri e r a 1 p r o c e d u r e? s a r e a v a i 1 a ta 1 e f o y- t h e p r e p a i- a 11 o n o f 
lip o s o en e s a s d e s c r" i b e d b e low; 
PREPARATION OF LIPOSOMES 
Multilamellar liposomes (MLV) 
The simplest method for preparation of liposomes was 
originally described by Bangham (1965). In this, 
phospholipids arB dissolved in a mixture of organic solvents, 
which is then evaporated to make a thin dry film. This film 
of lipid IS then dispersed in water at a temperature above 
th£5 phase transition temperature (Tc) of the highest melting 
component m the lipid mixture. 
The time of hydration and the conditions of agitation 
play a major role in the encapjsul at i on. Longer the duration 
of h y d r a t. i o n , ri :i. g h er w ill b e t i-'i e eri c a pi su 1 a t i on . 
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Small Unilamellar Liposome (SUV) 
Multilamellar vesicles prepared above are sonicated 
either by probe type sonicator or by bath type sonicator to 
give a clear suspension of liposomes. Small unilamellar 
vesicles can be separatted -from MLVs by ul tracentr i f ugat i on or 
by column chromatografjhy on Sephairose 2B, Sepharose 4b or 
Sephatdex G-50., The encapsulation e-Fticiency is howev&?r very 
low (4-7X) This method gives a mixture of homogeneous 
vesi cles. 
Detergent dialysis Method 
This method was developed by Racker et. -al • (70). In this 
m e t hi o d d e t e r g e n t s 1 i k e c h o l a t e , d e o ;•; y c h o 1 a t e, n •  - o c: t y J. g 1 u -
CDside etc. ars used to solubilise the lipid and the 
detergent is remov6?d Iny dial/sis in a control le;d manner. A 
number of 1 i pasome pr epar at i on systems are avai 1 ab 1 e f or t.hi i s, 
purpose. The ratio of lipid to detercjent is an important 
parameter for the type of liposomes. About 12% of solute can 
be encapsulated by this method. The major advantage of this 
method is thaxt liposomes are homogeneous-
Ethanol injection method 
In this method phosholipids dissolved in ethanol are 
r a p' i >:i 1 y i n j e c t e d i n t o a b u f f e r s o 1 u 11 o n w h e i'- e t h e y s p o n t a -
n e o u s 1 y f o r' m s m a 1 1 u n i 1 a m e 11 a r v e s i c 1 e s, iM e a i'-1 y a 1 1 v e s it:; 1 e s 
•f oI- med b y t: hi i s met h od ar e un i ]. a m e 1 1 ar . T'I"i e ma..:i or d r awb a c k 
• 0 
i s that. the ci i sper si on i s d i 1 utBd and the eucap 5u 1 a11 ov. 
efficiency is poor. 
French Press method 
Here, MLVs Are prepared according to Bangham' <s^  
procedure and instead of sonicai:ion, the^  dispersion of iii...,vs 
are: extruded through a French F'-'ress Cell at 20,000 Lbs/in at 
D 
4 C. This dispersion has vesicles in the size range of 250-
o 
500 A further extrusions yield more homogeneous preparations 
of SUVs-
Reverse phase evaporation 
By this method LtiVs can be prepared from a mixture of 
phospholipids and organic solvents. Diethyl ether or a 
mixture of diethyl ether and methanol is injected into an 
aqueous solution of the material to be encapsulated at 
D 
55 65 C under reduced pressure. The solvent is removeo by 
e V a pi o r a t i o n a n d 1 a r g e u n i 1 a m e 11 a r v e s i c 1 e s o f m e^  a n s i z e i 5 0 0 
c:) 
2500 A are formed. This method is suitable? for encapsulation 
of macromolecules. The disadvantages of this method mcluae 
exposure of material to organic solvents and to higl'i 
tempei--atur"e, and pr oduc t i on of hiet erogeneous popu 1 a11 or, of 
liposomes. The entrapment effeciency is quite high (up to 
<'> 5"''" > " T hi i s iTi e t hi o d i s h o w e v e r n o t a p p r o p r i a t e + o r 
encapsulation of proteins that get denatured on exposure to 
o I" q a r "I i c s o 1 v e n t s. 
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Rehydration dehydration Method 
This method developed by Kirby and Gregoriodis in 1984 
is employed for the large scale preparation of liposomes 
which are prepared by dissolving lipids in organic solvents, 
followed by the removal of solvent under reduced pressure and 
subsequently dispersing the lipid film in aqueous phase. 
The liposome preparation can be freeze dried and can be 
stored froisen without any major leakage of entrapped material 
for more than a year- Liposomes can be regenerated from this 
free:;;e dried lipid by adding water whenever required. 
The major advantage of this method is that the lipid 
powder could be stored for a long time and is ;suitable for 
diagnostic purposes as it is easy to prepare whe?n desired. 
Application of liposomes 
Since the discovery of liposomes by Bangham, therte has 
been tremendous activity in the use of liposomes in diverse 
areas of research. 
Initially liposomes had been exploited as a model 
membrane for numerous physico chemical studies because 
intact cell is a ve^ ry complicated system and the study on a 
molecular level is very difficult, if not impossible. These 
studies are better done with liposomes as they can give good 
clues regarding possible role of a particular component in 
r e 1 at i on tcj cell 1 i gand i nter ac t i ori under def i ned 
experimental condtions. These studies are based on the 
interaction between the ligand and the receptor. In 1975, 
Surolia et.al. devised a simple model system where receptor 
ligand interaction could be studied under defined 
experimental conditions. In these studies, GM containing 
1 
lipcascsmes (MLV, SUV) were made and their interaction with a. 
specific lectin -from Ricinus communis beans vjsis investigated. 
On the basis of various kinetic parameters e.g. association 
constant and rate o-f cluster -formation they concluded that 
liposomes could be used as a model system to study the 
receptor ligaind interaction (60). 
Since the last decade, there has been a spurt m the 
activity oi the use of liposome as drug delivery system and 
also in ^ .•.•niiunology. In 1971, Ryman and her coworkers were 
first CO recognise the potential medical application of 
liposomes as drug carrier and emphasii^ed the possibility of 
their use in the treatment of various metabolic and 
physiological disorders <72). 
The potential application of liposomes m immunoioq, 
was first described by Allison and Gregoriad.s m 1974. The.. 
showed the immunoadjuvant effprt nf i-i r-.r-,-,.-
--Tect. Of liposomes for the antiger 
diptheria toxoid. Since then, the ^ x-plni t .f,.- -
as adjuvant, immunomodulator and also ^<. 
tool has been a subject of an increasina ,- ^ 
easing ,u,mber of studies 
io cdver all the above areas is bevonri fh-
oevond the scope of th, 
discussion. Since the nrf:.<.-«r.+. 
present investigation has b.. 
directed towards the use of linnsnmo.. 
Ltposomes as drug carr^er^ n 
emphasis will be given on th,-, particr " 
•* P-^ f^ ticular aspect. 
Liposome as drug carrier 
Since the pioneeering work of Ryman et. al . (7'2) in the 
area of liposomes for drug delivery system, liposomes have 
been extensively used as a drug delivery system because most 
of the drugs which are in use for the treatment of several 
diseases, are not free from adverse side effects. Moreover, 
their specific targeting and proper tissue distribution is 
not feasible because of random uptake by tissues. Much 
rese^ airch has been conducted to target the drug spe?ci f ical 1 y 
to the disease affected site and to dervelop drug formulations 
which could reduce drug toxicity. Liposomals, are easily 
biodegradable? and can be made immunologically inert,, 
L i p o 5 o m e s; c a n a c c o m m o d a t e b o t h h y d r o p h i 11 i c a n d h y d r o p h o b i c 
drugs without any chemical modification in the structure? of 
the drug molecule. There are a number of parameters which can 
be conveniently altered like; size, lipid composition, surface 
charge and the membrane fluidity in order to deliver 
liposiomes to the appropriate site. Several workers have 
reported the use of liposome as a drug carrier m the 
t r" e a t m e i-i t o f 1 e i s h m a n i a s i s (73) , m e t a b o 1 i c d i s o r d e r s a n d 
fungal dise?ases (74), It has also been demonstrated that 
liposomally delivered drug can reduce the toxicity of the 
drug. Besides, by careful manipulation and suitable 
tailoring of liposomes, drugs may be targeted to specific 
organ(s). 
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In vivo -fate o-f liposome 
The clearance o-f liposomes from the circulation is 
controlled by various factors like liposomal size, surface 
charge and lipid composition. 
Studies have shown that majority of the liposome's 
inje?cted intravenously are retained in the liver and spleen 
re?gardless of liposome size, structural class or composition. 
The retention of liposomes injected i.v. in these organs ars 
primarily due to their uptake by phagocytic ceils m these 
organs. 
Studies have shown that large liposomes are cleared more 
rapidly from circulation as compared to small liposomes. This 
was inferred from the biphasic rate of clearance of liposomes 
which were heterogeneous. Juliano and Stamp m the/ir stud:i.es 
showed a more linear cleairance suggesting that the two phase 
clearance might be due to size heterogeniety (75). 
There are many factors which govern the retention of the 
solute in the liposomes e.g. the type of the liposome (MLV's 
o 
retain more than SaUV) , temperature (At 37 C thc-?re is more 
o 
leakage than at 4 C) and lipid composition (saturated 
phospholipids retain more than unsaturated phospholipids). 
EExperiments done in raxts showed that liposomes containing 
proteins were rapidly cleared from the circulation following 
intravenous injection, and were mainly taken up by the liver 
and splteen (76). Subcellular studies showed that the radio-
a c t i v e e n z y m e u s e d a s m a r I-; e r w as en a i n 1 y 1 o c a 1 i z e d i n t i-i e 
mi tochondriiu lysosomal -fraction^ By density gradient, 
centri-f ugati on thf3 lifsosomes were found to be ^Associated with 
the ly-'BOBomal -fraction ill). 
Intravenously injected liposomes can be successfully 
targeted to cells in different organs only if the liposomes 
are able to exit from the circulation and gain access to 
target tissues. The anatomy of microcirculation plays an 
important role in determining whether liposomes can gain 
access to e;-;travascul ar tissues (78--80) . 
According to the architecture of the endothelium lining 
and the underlying subendothelial basement membrane the 
blood capillaries can be divided into three main categories,, 
In the continuous capillaries, endothelium forms a continuous 
lining in which adjacent endothelium cells adhere via tight 
junctions^ The subendothelial membrane is also 
continuous. In the case of fenestrated capillaries the endo 
o 
thelium is interrupted by fenestrae which Are 300-800 A 
in diameter. The endotheliail membrane is spanned by a thm 
membranous diaphragm which is 4 ••- 6 nm thick. The 
subendothelial membrane is continuous. Discontinuous or 
sinusoidal capillaries are found only in the liver, spleen 
and bone marrow. They are thin walled and have larger gaps m 
the endothelium which may be of several thousand Angstrom m 
diametE^r. The basement membrane is lacking in most of the 
species in the case of liver but an interrupte?d basement 
membrane is present in these vessels in bone marrow and 
sp1een. 
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The diameter of the gaps in the endothelium would be a 
limiting -factor for the extravasation of the liposomes. The 
diameter o+ the gaps being 100 nm, small unilamellar liposome-?s 
can pass through such openings whereas larger liposomes are 
retained within the sinusoid. The opening of the 
endothelium of the hepatic sinusoids contain gaps larger 
than 100 nm and hence allow the penetration of multilamellar 
reverse phase and large unilamellar vesicles. However the 
frequency of th6?se openings is low and because of their 
irregular distribution the extravasation of large? liposomes 
is less efficient (78). Continuous and fenestrated 
capillari6?s are a major mechanical barrie?r to the exit of 
liposomes from the circulation. Liposomes are unable to 
escape from the micrcr-circulation in organs lined by either 
of the capillaries- Thus successful targeting is limited to 
a few tissues lined by discontinuous capillaries i„e. spleen, 
liver and bone marrow. Liver is compose-d of two types of 
cells mainly parenchymal cells (Hejpatocytes) and a smaller 
profjorti on of Kupffer cells which form part of the 
reticuloendothelial system. Some workers believe that 
liposomes Brei taken up by non parenchymail cells by their 
strong phagocytic activity and Sire responsible for most of 
the uptake (79). Electron microscopic and autoradiographic 
studies show that they are taken up by both types of cells. 
Studies done with liposomE? entrapped Horseradish peroxidase 
s |-1 o w e d an i n i t i a 1 in v o 1 v e m e n t o f K u p f f e r c ells a n d 
endothelial cells followed by parenchymal cells (£J0) . 
Targetting o-f liposomes 
Mechanistically, targetting o-f liposomes can be 
classi-i-i ed into 
(i) Passive targetting 
(ii) Active targetting 
The term passive targetting designates the natural 
localization o-f liposomes prepared -from phosphatidylcholine 
alone or in combination with cholesterol in the various 
tissues of the body after administration. Intravenously 
injected liposomes are preferentially taken up by mononuclear 
phagocytes of reticuloendothelial system in the liver, 
spleesn, bone marrow and in the circulating macrophages 
(monocytes). The potential utility of passive targetting has 
been successfully employed in the? treatment of visceral 
leishmaniasis. Leishmania is a parasitic disease mainly 
caused by L_^ donovani . The parasite predominantly resides in 
the macrophages of the liver and spleen. There are a number 
of drugs (Pentavaient antimonials, me?giumine antimoniate, 
scjdium sti bagl uconate and Amp--B) which are available taut the 
use of these drugs is limited due to hepatic, cardiac and 
renal toxicit. ies-
Alving et.al. <81) tested the effect of these drugs, 
incorporated into liposomes and found that antimonial drugs 
are 700 times more effective as compared to free drug in 
curing leishmaniasis. New et. al . (Ei2) also demonstrated that 
liposomal formulation of Amp-B is more active against 
^o 
visceral leishmaniasis in mice. In the case of spleen 
1 CD c a 1 i z: e d b a c t e r i a 1 i n -f e c t i o n Listeria monQcytoqenes i n 
experimental mice, liposome entrapped ampicillin was found to 
be? SO fold more effective in reducing the? bacte-?rial count 
compared to free drug. 
The issue? of targetting liposome?s to spe?cific tissues 
has attracted ccjnsi derable interest but the maximum uptake by 
organs rich in reticuloendothelial syste?m restricts its 
maximal utility in the biological system. Targetting of 
liposomes to specific tissues requires a recognition marker 
on the:^  surface of liposomes. This has been achi6?ved by 
modifying the liposomal surface with ligands like sugars, 
antibcjdies or other molecules that have specific affinity for 
those cells, F~Dr effective targetting, liposomes can also be 
designed to re?lease their contents under controlled 
conditions. This includes pH sensitive (83) as well as 
temperature dependent liposomal systems (84), 
Ryman et.al. (1971) reported the use of liposome 
encapsulated enzyme for delivery into cells (72). Around the 
same period, Ashwel1 and Morel! (85-87) in a series of 
brilliant experiments, demonstrated that a specific receptor 
on hepatocytes mediates clearance of B-galactose terminated 
glycoproteins from circulation. A specific receptor on the 
cell surface of the reticuloendothelial system of rats 
including the liver sinusoids as well as macrophages was 
recognised by Stahl et.al. (88). 
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Encouraged by these observations Ghosh et_._ a_l ,, 
demonostrated that by grafting different glycosides on the 
surface of liposomes it is possible to direct the latter to 
different cell types of rat liver (89). Galactosyiated lipo-
somes are mainly take?n up by the liver hepatocytes while 
mannosylated liposomes are taken up mainly by non-parenchymal 
cells (90), This sugar specificity was completely abolished 
if asialofetuin was injected along with the asialo GM lipo-
1 
somess. Similarly there was a partial decrease in the uptake 
of mannosylated liposomes when mannan was used as competitive 
inhibitor. 
Stability of liposomes 
LiFJDsomal stability has been the focus of much 
attention of many workers. Work has been going on, to 
increase the shelf life of liposomes. The drawback of 
liposomes is that, they cannot be stored for a long time prior 
to their use as they are prone to aberrations in their 
structural and functional properties. 
Disachharide sugars in this regard have played an 
important role in increasing the stability of the liposomes. 
It was found that, liposomes when freeze dried in the 
presence of trehalose, retained most of their structural and 
functional integrity on rehydration (91), Membrane structure 
is preserved by trehalose probably due to specific 
intesraction of sugar with the phospholipid head groups (92) 
This causes a depression in the transition temperature and 
3U 
subsequent maintenance of the liquid crystalline phase in the 
dry liposomes. Trehalose and sucrose were found to be the 
most ef f t?c t i ve i nthis regar d. 
Other factors which may play an important role m the 
stability of liposomes are lipid oxidation and the presence 
of contaminants in the lipids. Physical properties 3.re also 
attribute^d to play an important role. Multilamellar vesicles 
pirepared from palmitoyi phosphatidyl choline, cholesterol and 
dicetyl phosphate showed low leakage? of the solute even over 
a period of one year. Small unilamellar vesicles contstming 
cholesterol rejmamed stable for at least 53 days without any 
1eakage (93). 
io. vi 'vo fate of intravenously administered liposomes is 
an almost immediate release of entrapped solutes in the 
circulation due to its interaction with plasma high density 
lipoproteins (94). The exchange of phospholipids from the 
liposomes takes place through the interaction of HDL. This 
occurs as a consequence of col 1isions,when a sufficient ratio 
of apo-HDL to phospholipid ratio is attained. The resulting 
apo~HDL liposomes break down to smaller particles besaring a 
portion of the liposome derived lipids and of a size similar 
to that of HDL. This suggests that HDL has an ability to 
remove phospholipid from vesicular membrane and causes lysis 
of lipcisomes. This transfer of phospholipid by HDL can be 
minimised by — 
i) incre?asing the amount of cholesterol. 
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ii) using a phospholipid which undergoes thermal phase 
o 
transition at temperatures greater than 37 C and 
iv) structural modifications of PC. 
This obstacle can tae overcome by adjusting the 
choleste^rol content in the lipid bi layer. Permeability of 
various solutes from liposomes in the circulation can be 
minimized by the addition of cholesterol. It has been shown 
that the gre?atest stsibility can tae achieved by using 
equimolar amount of cholesterol and phospholipids in the 
liposome preparation (97). The stabilising effect of 
cholesterol in liposomes prepaired from other phospholipids 
wats si mi 1 ar ,, but this ef f ect was not so pronounced wi ti~i 
di 1 aur• oy 1 phosphat i dy 1 ci-io 1 i n£? (98). The permeab1111y ot 
1 i p o s D m e i s c o n t r o 11 e d ta y 1-^  e a d group interactions (95). T h e 
permeability increases with increasing temperature, 
decreasing chain length and increasing unsaturation (96). 
However, the? mechanism of cholesterol mediated stabilisation 
of liposomes is not very clear. It is suggested that -
i) packing of liposomes induced by cholesterol 
prevents the interaction of apo-HDL with the 
phospholipid. 
ii) The apo-HDL interacts with liposomes but the 
former is unable to remove the phospholipids due 
to tight packing of liposomes. 
F-'hosphol ipids in biological system B.rs mainly degraded 
by phospholipases. Among these, phospholipase- A selectively 
hydrolysGS C-2 bond o-f the ester group and most commonly 
present in liver cells. Stabilisation can also be achieved 
by exposing negative charge on the surface o-f liposomes. 
Th is has b een c on f i r med b y the in c op or at i on o-f g an g 1 i os i d es 
in the liposomes. A similar e-{-fect was observed with 
phosphatidyl serine containing liposomes (99). The ef-fect of 
si al ogl ycol ipids was more speci-fic in preventing the binding 
of immuno prote?ins to the liposomal surface. The gros-s 
physical structure of liposomes atlso plays an important roie-? 
in terms of stability. SUVs are cleared less rapidly than MLV 
while the neutral and positively charged SUVs 3.rB cleared 
less rapidly than the negati'vely charged SUVs. 
Guptai et. al • (100) successfully demonstrated that 
liposomes can be s'tabilized by the structural modification of 
phosphatidyl choline. The?se workers succesisf ul ly introduced 
an NH residue adjacent to the carbon aitom of their C~2 ester 
group, without adversry affecting the ph-ysi cochemical 
proprties of the phospholipid molecule. Liposomes prepareKJ 
from these structurally modified phospholipids lead to more 
ordered packing and hence decrease transfer of HDL (101). It 
also pre-v'ents the serum induced leakage of entrapped solutes 
and resists th£5 phosphol i pase A--2 action in the liver. Such 
liposomes are stable in the blood circulation for longer 
t i mB. 
Limitations in the use o-f Liposomes as Drug Delivery System 
The wider application of liposome as a carrier (in vivo) 
has several limitations. 
l,a) Uptake o-f liposomes by reticuloendothelial system 
A major portion of the i.v. injected liposomes are 
taken up by the mononuclear phagocytic cells of the 
reticuloendothelial system <102) and as a result, other 
tissues have little access to the injected liposomes. 
b) The Endothelial Barrier 
The use of liposomes as drug carriers for treatment of 
solid tumor where the vesicles have to pass out of 
blood stream is restricted because of the endothelial 
barrier. It has been demonstrated by Poste et al (103) 
o 
that MLV or SUV (600 A diameter) can not cross the 
pulmonary endothelia to reach the alveoli. They 
suggested that the liposome material in the alveoli had 
been cstrried by diape^desis of monocytes. Liposomes are 
able to cross the endothelium when there is a tissue 
damage because of certain disease. Application of 
liposomes through oral route or delayed release of 
liposomes by the use of pH sensitive or temperature 
sensitive liposomes does not need to cross the barrier. 
So where the endotheliaa barrier is a problem one 
can look for other routes of drug delive^ry systems 
u s i n g 1 i p o s o m e s. 
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c) Effect of Immunoadjuvant properties of liposomes 
In cancer chemotherapy lipcjsomes containing 
chemotherapeutic drugs could be targeted to cancer cells 
by coating monoclonal antibodies (Mab) raised against 
tumor cell specific antigen. This therapy has not proven to 
be useful because of immunoadjuvant effect of liposomes. 
Chemotherapy requires repeated injections of the liposome 
encapsulated drug and this misy lead to production of 
antibodies against Mab. So before drug is targeted to a 
specific cell type, liposome grafted Mab will be neutralised 
by anti Mab-antibodies and thus efficient drug delivery will 
not be achieved. Basten et. al. (104) suggested an approach 
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to overcome this difficulty. They used I labelled antigen 
on liposomes surface due to which immune reactive 
lymphocyte was damaged. This "Antigen suicide technique" may 
be useful for drug therapy using liposome grafted 
monoclonal antibodies against tissue specific marker, but the 
approach needs proper and caxreful evaluation. 
Advantages of using liposomes 
Liposomes have distinct advantages of being nontoxic 
and taiodegradable,as they are composed of naturally occurring 
lipids. Biologically active materials encapsulated within 
the liposomes are protecte?d to a great extent from immediate 
dilution or degradation. These properties of liposomes make 
them promising drug carrier systems for the transport of 
drugs or other taioactive molecules to disease affected organs. 
From the point of view of drug taxrgetting, the relevant 
question is - how does the carrier device interact with the 
target cells? The liposome cell interactions which can take 
place Brei 
i . The peripheral liposomal membrane may be -fused with the? 
plasma membrane leading to the release of vesicular contents 
i n t o the c y t o p1 a sm-
2. Exchange of lipids between liposomes and plasma 
membrane or adsorption of liposome to the cell surface 
without internalisation of liposomal contents. 
3. Liposomes may be taken up by the cells t:hrough the 
process of- endocytosis. 
Fusion of the liposomes with plasma membrane provides 
an attractive method for the introduction of hydrophilic 
molejcules into thie cell cytoplasm cjr lipophilic molecules 
into plasma membrane. In this process cellular organelles 
may become accessible to the material entrapped, though the 
e V i d e nee is c o n t r o 'v' e r s i a 1 „ M any w o r k e r s be! i e v e t h a t a 
fraction of liposomes abscjrbed on to cells does indeed fuse; 
with those cells (106). Generally, e^ndocytotic process is 
thought to plaiy the most prominent role in the upte^ke of 
iiposomail contents leading to its sequesteration in the 
lysosomal apparatus of the cell (107). Endocytosis has been 
divided into two typess phagocytosis, covering the 
internalization of larger particles and pinocytosis 
describing the uptake of smaller particles like lipoproteins, 
SUVs, and low molecular weight solutes. 
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EndocytoBis of liposomes by cells may be facilitated by 
grafting specific ligands to the liposomal surface. Model 
membrane studies have identified that the density of ligand 
on the surface of liposome plays an important role; in the 
lig<and receptor interaction. Poste and Papahadjopoul ous 
demonstrated that the uptake of liposomes by cell fusion or 
endocytosis is dependent upon the fluidity and surface charge 
of liposomes (103). The predominance of any of these 
me^chanisms is controlled by the chemical and physical 
properties of liposomes, like vesicle size, surface charge, 
lipid composition, and density of ligand. 
Liposome as Antifungal drug carrier 
The polyene antibiotic treatment of most fungal 
infections is usually straiight forward but systemic use of 
polyenes is limited due to their toxicity in biological 
system. In an attempt to re^duce the toxicity of Amp-B, several 
derivatives have been made. The important ones which have 
been studied for antifungal activity and toxicity are methyl 
ester of Amp-B (109) and its N-d-orthonyl derivatives, N~ 
propionyl-SH Amp-B, (110) and N 1-deoxy-D-fructose-1yl (111) 
derivative. Most of the derivatives show either equal or 
less antifungal activity without any significant reduction m 
drug toxicity- Furthermore the derivatisation process 
involves a number of cumbersome chemical steps due to which 
several derivatives of Amp B have not gained acceptance as an 
antifungal measure and have rather remained a subject of 
ac ad em i c i n t er est:. 
.:••/ 
In recent years, liposomes have been 
exploited as a drug carrier -for antifungal agents like Amp-B, 
5 - fluoruracil, grisofulvin. Our area of interest being 
liposomes as carriers for Amp-B, discussion will be 
restricted tcj the potential usefulness of liposcjmal Amp-B» 
Amp --B is e^n i d eei 1 c an d i d at e for i n c or p or at i on i n t o 
lifiDsome because? of its amphipathic nature and its ability to 
integrate into biological lipid membranes. Administration of 
Amp-B intercalated into liposomes is an effective way of 
reducing its toxicity in biological systems. In 1981, New 
et. al. (82) incorporated Amp-B into liposomes and 
demonstrated tha^ t liposomal Amp-B is less toxic as compared 
to deoxycholate stabilized formulation of fungizone. They 
also showed that presence of sterol in the liposome 
prep£iration markedly increased LII> from 31.2 mg/kg for 
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lecithin liposomes to 14 mg. This is likely to be related to 
t he af f i n i t y of sterols f or Amp~B. 
It was observed that the degree of saturation of 
phospholipids plays an important role in reducing the 
toxicity of Liposomal Amp-B. Liposomes composed of 
phospholipids with saturated acylchains are non toxic, 
whereas liposome intercalated Amp-B composed of phospholipids 
containing unsaturated acylchains are almost as toxic as 
Amp B (112). The reduction in toxicity of liposomal Amp B m 
the presence of sterol and also with saturated phospholipids 
might be due to an increase in their order and stability and 
thus decreasing the flux of molecules across the membranes. 
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Since t Y\e 1 ast decade, much i r 11er e<s>t has taeen c en te^ r eci 
on the use of liposomes as a drug carrier tor Amp-'B in the 
treatment of several pa.raBitic. and sv'stemic -fungal mfecti. ons. 
New et. al . (82) have demonstrat63d that Amp-B intercalated 
into liposomes is less to>;ic and more effective in the 
treatment of leishmaniasis than Amp-B. In vitro studies by 
Juliano et. al ,, <! 984) suggest that liposomal Amp B prepared 
f r o fci d i m i r i s t o y 1 p h o s p h st t i d y 1 c h o 1 i n e and d :i. m i r i s t o y ] 
phosphatidyl glycerol is to>;ic to fungal cells taut not to red 
b 1 ood cell s ( 113)'. In case of severe i rif ect i ons sue|-i as 
h i s t o p 1 a s fii o sis (114), c r y p t o c o c c o s i s (115), c a n d i d i a s i s (116) 
lipcjsomal Amp-E! has been shown to be le^ss to;;ic than 
fungizone but retains similar antifungal activity„ The 
r educ t i on i n t o;•; i c i t y a 11 ows the use of h i gh er dose of Amp B 
thus improving therapeutic index. There are conflicting 
r e p o r-1 s r e g a r d i n g the the r a p e u t i c e f f i c: a c y o f 1 i p o s o m a 1 Amp- B 
in the treatment of fungal infections. Taylor et„al. (117) 
have shown that at equal doses of liposomal Amp B with that 
of funge^sone the iiposomised Amp--B was not as effective as 
the comercial Amp-B in the treatment of experimental 
candidiasis. Juliano et al have also checked the therapeutic 
efficacy of liposomal Amp-B and commercial Amp B in the 
experimental model of caxndi di asi s„ They found that animal 
survival rates with the two formulations at equal dosage of 
A m p B we r e s i m i1 a r (118). Ss o k a's obser v at i on s (119) seem to 
lend support to the boosting effect of liposomal Amp-B on its 
1:herapeLt t i c: i nde;•; „ 
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The role of sterol in the liposomal formulation of Amp-E-ii 
was also investigated in the treatment oi experimental murine 
candidaisis by Jiuiiano et. al- <120). These workers have shown 
that there is no significant difference in the survival time 
of mice infected with Can^d.^^. al bi cans treated with sterol 
containing liposomal formulation of Amp-B compared with those 
treated with sterol free liposomal Amp-B. The tissue 
distribution o^ free and 1 iposomai ftmp-~~B has been reported by 
Lopez-Berestein in normal as well as in infe^cted animals 
(121)„ An attempt has also been made by Szoka et.al. (122) to 
study the tissue distribution pattern of Amp-B in egg 
p h o s p I-) a 11 d y 1 c h o 1 i n e / c h o 1 e s t e r o 1 /1 o c o p h e r o 1 a c i c;l sue c i n a t e 
1iposome in normal mice. 
Encouraged by these findings Lopesz-Berestei n, (123) and 
Soulier et. al . (124) have done clinical trisils to treat 
Aspergillosis in cancer patients with liposomal Amp-B and 
found that liposome associated Amp-B offers better therapy 
t h a n f u n g i z o n e. 
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AIMS AND OBJECTIVES 
Amphoterici n-B in pc\rtic:ular and polyene antibiotics in 
general have been widely used in clinical practice to treat 
various systemic -fungal in-fections such as candidiasis, 
histoplasmosis Aspergillosis etc. The severe tD>;icity of the 
drug such as nephrotoxicity, azotemia,renal tubular acidosis^ 
hypokalemia, fever, etc. impose a potential barrier in the 
exploitation of Amp--B as a profier therapeutic measure. 
Chemical derivatisation of the drug has been done to 
eliminivte? such side effects but these Bra far from ideal fi/r 
therapy. In recent yeatrs, lot of attention has been pai i in 
the use of liposome as drug carrier tc, nome the drug to 
specific sites which in turn could reduce the toxicity and 
improve therapeutic efficacy. In case of various fungal 
d i !~'- .:t s e s B u c h a s C a n d i d i a s i s , H i s t o p 1 a s m o s i s, C r y pi t o c:: o i c;: o s i s 
1-',|JDsomes have been used as a drug carrier for Amp--B in 
experiiTicental animals, F';e suits from various laboratories 
indicate that liposomal Amp-B is less toxic while being 
equally effective in curing fungal infection, and could 
pBr ant the use of a high amount of drug, which otherwise 
would be toxic in free form. Encouraged by the promising 
results of reduced toxicity of liposom^il Amp-B in 
candidiasis, some workers attempted to use liposomal Amp B in 
the treatment of aspergillosis in cancer patients. However 
<123 124) no attempt hais been made to evaluate the 
1: h e r a p e u t i c e f f i c a c y a n d t o x i c i t y o f 1 i p o s o m a 1 A m p B i n 
experimental animals which deserves proper study before the 
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•formulation enters into evaluation for clinical trial in 
humans. Keeping this in mind the present investigation 
attempted to develop a suitable animal model tor 
aspergi 1 iosis in EHALB/C mice which could provide a systemic 
evaluation of the therapeutic e-fticacy of liposomal Amp-B and 
free drug. 
Once the suitable animal model has been developed it is 
necessary to select the parameters for clinical evaluation of 
the drug. The toxicity of the free and liposomal f^mp-B has 
been done to find out a dose permissible for use in therapy. 
Sesveral manipulations in liposomal formulations have-; been 
done by altering lipid composition in an attempt to have a 
suitaible formulation that is less toKic and more effective. 
In case; of experimental candidiasis, the therapeutic 
efficacy of liposomal Amp--B has been checked by the survival 
of animals after therapy and the fungal load in disease 
affected organs. In the present investigation a similar 
approach i.e. the determination of survival and CF-'U have been 
taken as parameters to evaluate the efficacy of liposomal and 
ireei drug. 
The concept regarding the role of macrophages as a 
secondary drug carrier for liposomal drug is becoming a major 
i ssiiue. I n an atternpt to ascertai n whether macrophages p 1 ay 
a definite role in the liposomal delivery of Amp-B, a 
liposomal device? has bee^ n made with man nose grafted on its 
surface. The idea of grafting mannose, originated from the 
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well documente-?d -fact that, macrophages have receptors for 
manriDSB. Such a device will enable one to target drug to 
rnacrophagess and thereby improving drug uptake. Besides, i+ 
macrophages happen to foe the carrier cells, an improvement 
i n ther apeut i c: e + -f i cacy would be observed. The p rasen t 
thesis -focuses on this particular issue of the role of 
macrophages with special emphasis on its role m the 
targeting of liposomal drug. 
It has been shown by Lopez-Berestei rr's group that 
liposomal encapsulation of Amp~B could alter the organ 
concentration of the drug and more drug gains access to the 
d i s €? a s e d site and t hi u s imp r o v i n g t h e t h e r a p e u tic e f f :i c a c;: y 
(121). Whether similar explanation hold true experiments 
have been designed to study the tissue distribution of 
liposomal Amp-B by the quantitation of the drug using HPLC, 
It is quite reasonable to postulate an altered tissue 
d i s t r i b u t i o n p a 11 e r" n in infected animals as c:: o m p a r e d t o 
normal;, because infection is always associated with damage in 
various tissues and Ca-Apilaries and altesration in the 
properties and population of various cells that 3.re involved 
in the defence? process. The present work also focuses on 
this issue and tries to study the tissue distribution m 
normal as well as in infected animals. Search for a suitable 
explanation for the improved theerapeutic efficacy m the 
light of these observations has also besen attempted. 
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CHAPTER 2 
MATERIALS AND METHODS 
MATERIALS AND METHODS 
11.1. Chemicals: 
Amphotericin-B (Amp-B), Stearylamine (SA), dipal mi toy! 
phosphatidyl ethanol ami ne (DPPE) , yeast mannan, p--a.mi nophenyl 
OC • D ~ m a n n o p y r a n o s i d e, a n d g 1 u t a r a 1 d e |-i y d e, w e r e p u r c; f "i a s e d ir o m 
Sigma chemical Co. St» Louis U.S.A. Trinitrobenzene Sulpnonic 
acid (TNBS) was obtained from Fluka, Switzerland 
f^'hoephatidyl EJerine was purchased -from Avanti polar Inc., 
U.S.A. Egg phosphatidyl Choline (E-IPC) and cholesterol (Choi) 
were purchased from CSIR, Centre for Biochemicals Delhi, 
India. Fungizone the deoKycholate preparation of Amp-B, was 
obtained from Sarabhai Chemicails, India and was 
reconstituted in 5X dextrose before use. Concanavalin A 
w£^ s prepared according to thie method of Surolia et. al. (125) 
All other reagents used were of the highest purity available. 
11.2. Animals: 
Male BALE-i/c mice (body weight, 20-30 gm ) were purchased 
from the Laboratory Animal Facility of Central Drug Research 
Institute, Lucknow India , and maintained in our animal 
house, 
11.3. Fungus : 
Fungus used in course of this study was Aspergillus 
fumigatus Strain VP 256. The Strain VP 256, isolated from 
ari I ri d i an p a t i en t, was kindly provided b y Dr. Z . Li. i-; h a n o f 
V P C h e? s t Inst i t u t e, Delhi. 
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11.4. Preparation of medium used for cultaring Aspergillus : 
The Sabouraud dextrose medium used for Aspergillus 
culture was prepared as follows. Agar 20gm, Glucose 20gm and 
Peptone 10 gm were diluted to 1 lit with distilled water and 
the solution was autoclaved. 0.05 gm chloramphenicol was 
added aseptically to the solution and the final broth was 
poured in tubes to make slant cultures. The organism was 
o 
cultivated in these slants by incubation at 37 C for 2--3 
days. The grown spores of Asperqi11 us fumi qatus were 
suspended in 0.15 (M) sterile saline and counted on a 
hemocytometer. 
11.5. Animal Model : 
Since Asptsrgi 1 losi s is a systemic fungal infection among 
the immunocompromised patients, it was felt., that immune 
status of the mice should first, be suppressesd and then 
followed by the injection of Asperqi1lus fumiqatus spores, in 
order to get the proper fungal infection in the lungs of 
experimental mice. The drug used to suppress the immune 
status of the mice was cyclophosphamide. Different 
concentrations of cyclophosphamide (50-150 mg/kg body wt) 
were used. Groups of animals were infected after 24 hr of 
cyclophosphamide? treatment with 0.17 ml of 0.15 M Saline 
7 7 
containing varying number of spores (15 X 10, 7.5 X 10, 3.5 
7 
X 10 ) via the tail vein. In all these experiments no 
animal survived after the first day of injection of 
A. fumiqatus. Varying number of fungal spores (15 X 10 , 
7 7 7 
7.5 X 10 , 3.5 X 10 , 1.8 X 10 ) were also injected without 
prior injection of cyclophosphamide- It was -found that all 
7 7 7 
the animals infected vjith 15 X 10 , 7.5 X 10 , 3.5 X 10 died 
7 
within 2-3 days, taut a spore dose of 1.8 x 10 caused 
disseminated fungal infection and the animals survived for 2 
days proividing sufficient time for evaluation of therapeutic 
efficacy. 
II.6. Preparation of liposomes s 
Liposomes were prepared from phospholipids with or 
without cholesterol. Amphotericin-B (Amp-B) was intercalated 
into liposomes, wherever needed. Different formulations of 
liposomal Amp~B were used. The molar ratios of phospholipid 
with the types of liposomal formulation of Amp-B are 
ment i oned below:-
Types of formulation Molar lipid ratio 
EF-'C 1 
EPC:Chol 7:3 
EPC:SA 7:1 
EPC:Chol!SA 4;3:1 
EPO.PS 9:1 
EPCsCholjPS 6:3:1 
EPC:Chol:DPPE 6:3:1 
EPC:DPPE (Mannosylated) 9:1 
EPC:CHDL:DPPE(Mannsylated) 6:3:1 
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In general, 45 mg of lipid was dissolved in 2:1 
chlcsro-form : methanol in a round bottom -flask, 1 mg Amp~B 
dissolved in methanol (40 ug/ml) was then added. The solvent 
o 
was then removed under reduced pressure at 37 C and the flask 
was kept in vacuum dessicator overnight to remove residual 
sol vent. 
The thin dry -film was resuspended in 0.15 M sterile? 
o 
saline and sonicated for 45 min at 4 C under nitrogen 
atmosphere using water bath sonicaitor (Model-decon FS-200, 
Ultrasonic Ltd. England). The liposomal suspension thus 
o 
obtained was dialy;:ed at 4 C against 400 volumes of 0.15 M 
NaCl which was changed two times over a period of 12 hr, to 
remove non intercalated Amp-B. Liposomes without 
intercalated Amp-Ei were also prepared according to the saime 
procedure as described above. 
11.7. Covalant Coupling of p-aminophenyl ,(X-D manno-
pyranoside to dipalmitoyl phosphatidylethanolamine s 
Covalant coupling of p-aminophenyl CC , D mi^nnopyrano--
side to dipalmitoyl phosphatidyl ethanolamine liposomes was 
done according to the method of Torchilin et.al. (126) with 
slight modification. Phosphatidylethanolamine liposome 
suspension (20-30 mg lipid) in 0.15 M NaCl was mixed with 
5 mg (contained in 1 ml) p-aminophenyl- OC - D mannopyrano 
side. Glutraldehyde was added slowly to the liposome 
suspension upto 15 mM final concentration and the mixture was 
o 
allowed to react for 5 min at 20 C. Uncoupled p--ami nophenyl 
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- OC - D mannapyranoside and gl utaraldehyde were? removed with 
two washings by ultracentri+ugation. 
U.S. Monitoring of coupling of p-aminophenyl-OC - D manno-
pyranoside to dipalmitoyl phosphatidylethanolamine liposomes. 
The coupling o-f the mannoside on liposomes was 
monitored by : 
Titration of amino group of phosphatidyl ethanoiamine :i.n 
liposomes with trinitrobenzene sulfonic acid: 
To 1 ml of liposomal suspension (0.5~1 mg total lipid) 
were added 1 ml of 47, NaHCO (pH 3.5) and 1 ml of :10X SDS. The 
mixture was kept at room temperature for 20 min and then 1 ml 
of 0. 1"<. TNBS solution was added. The reaction mixture was 
o 
allowed to react at 40 C for 2 hr. 
After 2 hr^the reaction was terminated by adding 0.5 ml 
of IN HCl- The absortaance of the solution was read at 335 nm 
against a blank treated as above but with 1 ml of water 
instead of the lipjosome suspension il2.6) . About 80-857. of 
phosphatidyl ethanoiamine amino groups were found to be 
modified, in all cases, by the above treatment. 
11.9. Preparation of Mannose grafted liposomes: 
Liposomes <total lipid 45 mg) without Amp-B were 
prepared having a molar ratio EPCsChoi:DPPE-Man (6:1:3) and 
EPC: DF'PE-Man (9: t) respectively. The lipid suspension was then 
lyophilised and dissolved in chloroform in a round bottom 
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•flask, 1 mg of Amp-B dissolved in meth£-inol was then added to 
it. The lipid Amp-B mixture was concentrated to dryness in 
rotatory evaporator and kept in dessics^tor overnight to 
remove residual solvent from the flask. The thin dry film 
was resuspended in 0.15 M NaCl and sonicated for 45 min under 
nitrogen atmospihere using bath type sonicator. The non 
associi^ted Amp-B was removed by extensive dialysis against 
o 
0.15 li saline at 4 C. The presence of mannose on surface of 
liposomes has been confirmed by agglutination of intact 
liposomes with Con A at 660 nm as described by Ghosh et.al. 
(39) . 
11.10. Assay of liposome intercalated Amp-B: 
The drug concentration in the liposome suspension was 
determined by two methods : 
<i) Spectrophotometric Method 
(ii) HPLC Method 
i) Spectrophotometric Method : 
The amount of Amp~B intercalated into liposomes was 
determined before and after dialysis by diluting a sample of 
the final preparation of 20 ui to 3000 ul in methanol, 
measuring the atasorbance at 405 nm, and comparing the 
absorbance with standard curve prepared form Amphotericin-B 
in methanol; the absorbance blanks consisted of equivalent 
amount of lipid dissolved in methanol. 
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ii) HPLC Method! 
The Amp-B content in liposome was also confirmed by 
HPLC analysis- The HPLC used for the analysis o-f Amp-B 
consisted of Eiynkotek Hodel (Munich, FRG) 300 C high 
precision pump with a solvent delivery system, an injector 
with 20 ul loop and dual wave length UV detector (Gynkotek 
UVD-160), A 0.005 M EDTA Methanol <3s7 vol/vol) was used as 
chromatographic eluent. A C reverse phase coloumn (250 mm X 
J. 8 
4.6 mm) was used for separation and the absorbance was 
recorded at a wave length of 345 nm. The analysis of the 
peak atrea was performed with the help of a PC-integrator 
attached with HPLC. To determine the retention time and peak 
area of Amp-B, 20 ul \in duplicate) of Amp-B from stock of 
2.5, 5, 10 ug/ml methanol was injected into HPLC coloumn. 
The peak area, obtained after injection of liposome 1 ysed with 
methanol was compared with that of Amp-B si-:andards to 
calculate the perce?ntage of intercalation of Amp-B. 
11,11. Standard curve for Amp-B in various tissuess 
The recovery of Amp-B from various organs by methanol 
extraction method was determined as follows: Tissue samples 
(0.5 g, in duplicate) from BALB/c mice were homogenised after 
adding 10 ug of Amp-B in 2 ml methanol. The samples were 
centrifuged at 9000 X g for 15 min. The supernatant was 
taken for HPLC analysis. An aliquot (20 ul) of supernatant 
was injected into column separately and the peak strea obtained 
in each case was compared with that of standard Amp-B to 
50 
calculate the recovery of Amp~B -for each tissue. The 
recovery of Ampj-B in liver and spleen was found to be 617, and 
75'/., while the recovery of Amp-B in lung and kidney was 74% 
and 617. respectively. 
11.12. Determination of LD : 
50 
Free Amp-B(Fungizone), commercially available form (0.5-
4 mg/kg) and liposome associated Amp-B (2.5-30 mg/kg) were 
injected into BALB/c mice (weight: 20-30 g, 10 animals in 
each group) via tail V6?in and survival was checked oyer a 
period of 4 days. In all these studies various liposomal 
formulation of Amp-B were? used as described in sections 
11.6 and 11.9. Median lethal doses (LD ) were calculated 
50 
by the formula: 
Log (LD ) = log dose (minimum + log ratio (f+1) as 
50 
described by Weil (127), 
11,13 (a) Treatment of mice infected with AspergiIIus 
fumiqatus : 
The antifungal activity of free and liposome 
intecalated Amp-B was tested in BALB/c mice infected with 
7 
1,8 X 10 Aspergillus fumigatus spores as described in animal 
model section ( II .5 ). BALB/c mice were injected via the 
7 
tail vein with 1,8 X 10 fungus spores. After 24 hr of spore 
challenge, infected animals were randomly.divided into four 
groups, each group containing 15 animals. Animals in the 
first group received either 0,25 mg/kg or 0.5 mg/kg of free 
il 
drug, and those in the second group were treaxted with either 
0.25 mg/kg or 0,. 5 mg/kg liposomal Amp-B. The control group 
received only liposome having same lipid content as m second 
group but without Amp-B, The fourth group was left 
untreated. 
The efficacy of the drug was evaluated on the basis of 
survival of animals along with number of colony forming unit 
(CFU) in lung. Survival was checked for 7 days after 
therapy. 
To study the fungal load, the number of CFU in lung was 
determined as follows: On various days, animals were 
sacrificed, left lungs taken out aseptically, and weighed 
and homogenised in sterile 0.15 M saline. A 10 fold serial 
dilution of lung homogenate was made and aliquots W6?re plated 
on sabouraud de;;trose medium. After incubation of the plates 
o 
at 37 C for 48 hr, colonies were counted. 
11.13 (b) Statistical analysis of CFU and survival: 
The CFU data were statistically evaluated by the method 
of analysis of variance* of one way classification with 
unequal frequencies as given by Snedecor ?< Cochran <148). 
Heterogenecity of means was tested by the F-ratio of 
treatment variance to the experimental error variance. The 
latter was used to find the standard error of difference 
between the pairs of means by calculating the observed t-
value and comparing it with the tabular t-value against 
degrees of freedom due to error. 
Data pertaining to survival were studied by using the 
CHI-square technique of 2 X k table? as given by Goulden 
(149). Since our interest was mi^ inly on the out come of the 
results on the 7th day <Final day) detailed eKamination of 
the results pertaining to the remaining days have not been 
presented altho\..igh the data was analysed completely. The 
comparision between paired sets were analysed and di-f-ference 
between pairs at p <0.05 level were considered. 
11.14. Tissue distribution of free and liposome 
intercalated Amp-B : 
The recovery of Amp~B from various organs by methanol 
extraction method was measured as follows: Tissue samples 
(0.5 g, in duplicate) from BfhLB/c mice we^ re homogenised after 
adding 10 ug of Amp-B in 2 ml methanol. The samples were 
centrifuged at 9000 X g for 15 min. The supernaitant was 
taken for HPLC analysis. An aliquot (20 ul) of supernatant 
was injected into column separately and the peak area 
obtained in each case was compared with that of standard Amp-
B to calculate the amount of Amp-B in each tissue. 
At 1 hr and 24 hr after intravenous challenge of either 
free or liposomal Amp-B, groups of six mice were sacrificed 
and different organs namely lung, liver, spleen and kidney 
were taken out, excised and frozen until analysis. The 
tissue samples were pooled, homogenised in methanol, 
centrifuged and the supernatant was taken for HPLC analysis, 
as described earlier. The amount of Amp-B in various organs 
was calculated on the basis of drug assayed by HPLC method 
after methanol extraction followed by multiplication by 
re^covery factor. 
Tissue disribution of Amp-B intercalated into mannose grafted 
liposomes: Mannan inhibition study: 
For mannan inhibition study, mannan in saline <80mg/'kg 
body weight of animals) was injected intravenously 5 min 
prior to injection of Amp-B intercalated into liposomes. 
After 15 min challenge of liposomal Amp~B, the animals were 
sacrificed and various organs such as lung, liver, spleen, 
and kidney were taken out, and processed for Amp~B deten:tion 
as described (11.14 ). 
CHAPTER 3 
RESULTS 
RESULT 
111.1. Animal Model -for in-Fection: 
Animal model of Aspergillosis in BALB/c mice 
was developed as described in the Materials and Methods 
section (11.5). It was observed that by challenging BALB/c 
mice with cyclophosphamide followed by the injection of A. 
fumiqatus spores caused their death on the ne^t day a-fter 
infection. Animal treated with varying number of fungal 
7 7 7 " 
spores alone <15 X 10 , 7.5 X 10 , 3.5 X 10 ) also died 
7 
within 2-3 days. However, an inoculum of 1.8 X 10 spores did 
not cause death upto 2 de^ ys after inje^ction and this dose was 
selected for all further studies. The lower doses of fungal 
6 
spores (l.a X 10 ) did not cause disseminated fungal 
infection. This provided sufficient survival time after 
injection for an evaluation of the efficacy of free and 
liposomal drug. 
111.2. Intercalation of Amp-B into liposomes: 
The intercalation efficiency of Amp~-B was determined 
as described in materials and methods section <II-10). The 
intercalation of Amp~B in various liposomal formulations was 
found to be more than 907. . 
111.3. Toxicity studies: 
The LD of free Amp-B (Fungis'.one) was found to be 
50 
1.2 mg/kg body weight. The value increased markedly after 
intercali^tion of the drug in various types of liposomes. 
The LD of Amp-B intercalated into various types of liposomes 
50 
is given in Table I. The LD of free Amp-B in BALB/c mice was 
50 
found to be 1.2 mg/kg body wt. Inte?rcal ation of Amp-B into 
liposomes irrespective of their compositions increased L..D 
50 
remarkably. The LD of Amp-B into neutral EF'C liposomes 
50 
was 5„3 mg/kg. Intercailation of Amp-B into positively charged 
<f£F'C/SA) or negatively (EPC/F-'S) charged liposomes further 
increases the LD , the values were 8.1 and 8.4 mq/kg 
50 
respectively. Inclusion of cholesterol in neutral liposomes, 
increases the LD value (8.5 mg/kg) as compared to EF'C 
50 
liposomes (5.3 mg/kg) without cholesterol. In ca'-:!- of 
negatively and positively charged, liposomes, cl-'clesterol 
inclusion had no significant effect or, L D . The LD values 
50 50 
with EPC/SA/Chol 5< EPC/F-'S/Chol was 8,7 and 9,0 mg/kg body wt. 
iiannose gratted EF-'C/DF'PE/Chol liposomal formulation of Amp B 
had the highest LD value which is 20.3 mg/kg body weight, 
50 
and without cholesterol it was 8.4. When mannose :i.s excluded 
from the composition (EPC/Chol/DPPE) the LD was 8,1 aig/kg. 
50 
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Table-I 
Toxicological Studies of various formulations of liposomal 
Amphotericin-B. 
Formulation LD 
50 
(mg/kg body weight) 
FreB Amp-B 1.2 
EF'C liposomes 5.3 
EPC:Chol iliZ) 8.5 
EPCsChol:SA (4:3:1) S.7 
EPC:SA \7:1) 8.1 
EPCsChol:PS (6:3:1) 9 
EPC:PS (9:1) 8.4 
EPC:Choi:DPPE (6:3:1) 8.1 
Mannosylated 1iposome 
EPC:Choi:DPPE-Man (6:3:1) 20.3 
EPC:DPPE-Man (9:1) 8.4 
111.4. EFFECT OF FREE AND LIPOSOMAL Amp-B <EPC/Chol :: 7:3) 
IN THE TREATMENT OF EXPERIMENTAL ASPERGILLOSIS AND ITS 
ALTERED TISSUE DISTRIBUTION IN NORMAL AND INFECTED MICE. 
111. 4.1. Treatment of in-fected mice: 
It was cabserved that more than SOX oi the 
animals treated with empty lipoBomeB died within three days 
a+te^ r in-fection and none survived a-fter 4 days. The animals 
treated with free Amp-B (0.5 mg/kg) led to significant 
increase in survival (IS'/l surviving 7 days after therapy) as 
compared to untreated animals none survived after 4 days 
of infection Table II. The animails which received a lower 
dose of free Amp-B (0.25 mg/kg) showed further improvement in 
survived (25X surviving 7 days after therapy) as compared to 
untreated animals (none survived after 4 days of infection 
Table III. 
The fungal count in lung was also reduced after free 
Amp-B treatment. The value of CFU in untreated mice after 24 
hrs. of spore challenge was SOIS which reduced to 3700 m 
mice treated with free drug (0.5 mg/kg) Table IV. In the case 
of mice receiving free Amp-B (0.25 mg/kg) the CFU in the lung 
was reduced to a value of 3775 Table V after 7 days of 
therapy. 
A remarkable increase in survival was observed in the 
case of animals treated with liposomal formulations of Amp-B 
as compared to free Amp-B. The animals which received 0.5 
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mg/kg and 0.25 mg/kg of liposomal intercalated Arnp-B (molar 
lipid ratio EPCs Choi s 7:3) had a higher survival index 707. and 
457. survival as well as significantly reduced fungal count to 
zero and 2225 respectively. However, the survival pattern 
of animals treated with Amp-B (0.5 mg/kg and 0.25 mg/kg) 
intercalated in EPC liposome was found to be 6*07. and 257. 
and the fungal count in the lung reached to a value of 625 
and 3037 respectively after 7 days of therapy. 
111.4.2. Free Amp-B 
The organ concentration of free Amp~B in various 
tissues namely lung, liver, spleen, kidney in normal and 
infected mice after intravenous administration of Amp-B are 
presented in Tatale-VI, and Table-Vll. In case of infected 
animals the initiatl concentration of Amp-B in lung increased 
by 1.7 times as compared to normal mice whereas after 24hr 
the concentration of Amp-B was comparable with tha\t of normal 
ani mal s„ 
In liver, the concentration of the drug was similar in 
infected and normal mice taut after 24hr the concentration of 
drug in infected animals decreases by 1.3 fold as compared to 
norme^l mice. 
The concentration of the drug in spleen of infected 
animals after intravenous administration was decr6?ased by 
2.2 fold as compared to normal animals but after 24 hr, the 
concentration of drug, was 1.7 times higher as compared to 
normal animals. 
The kidney concentration oi Amp-B in infected animau. s 
was 2.1 fold higher as compared to normal itnimals whereas 
this concentration -further increased by 6.3 fold in infected 
animals in comparison to that of normal ari.dals. 
111.4.3. EPC Liposomal Amp-B 
The tissue distribution patterns of liposomal Amp-B in 
normal and infected animals are shown in Tables-VI and VI In 
In lungs, the concentration of Amp~-B in infected mice was 8.6 
times higher than that in normal mice after Ihr. After 24hr 
the concentration of Amp-B in lungs in normal and infeced 
mice were almost same. In case of liver the initial 
liposomal Amp-B concentration in normal mice was higher by 
1„4 fold to that of infected animals whereas after 24hr the 
drug concEmtrati on in infected animals was 1,3 timEJs less as 
compared to infected animals. The concentration of liposomal 
Amp B in the spleen of infected animals was 3.9 fold higher 
as compared to normal animals after Ihr of liposomal Amp-B 
administration but after 24hr the concentration of Amp B was 
2.5 times higher to that of normal animals. In kidney, the? 
liposome associated Amp-E? in infected and normal animals was 
comparable after Ihr of intravenous administration whereas 
after 24hr the concentration of liposomisl axssociated Amp B 
w£is 3.3 fold higher in normal animals as compared to infected 
ani mals. 
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111.4.4. Amp-B in (EPCsChol::7:3) Liposomes 
The organ concentration of EF^ C: Choi : : 7s 3 liposomal 
Amp--B in normal and infected ani(nB.lB is given in Table?s VI 
and VII. The lung concentration after Ihr of liposomal 
associated Amp-B administration in infected animals was 1.2 
fold higher to that of normal animals but after 24hr the 
concentration of the drug was 1.1 fold higher. The initial 
concentration of liposomal Amp-B in liver of infected animals 
wats comparable to that of normal animals whereas the 
concentration of drug •^^)as 1.5 times higher in normal animals 
as compared to infected animals after 24hr of intravenous 
administration. In case of infected spleen, the concentration 
of liposomal Amp-Ef after Ihr of intravenous admi ni striiti on 
was 1.2 fold higher as compared to normal mice but the 
concentration of drug decreased by 3.6 fold after 24hr of 
drug administration. In kidney, the liposomal Amp-B 
concentration in infected animal was 2.5 times increased as 
compared to normal animals whereas after 24hr the 
concentration of Amp-B in both the cases become equal . 
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Table-II 
The in+luence of single doss of 0.5 mg/kg i.v. injected free 
or liposomes intercalated amphotericin~B on survival of 
7 
BAI_E;I/C mice intravenously exposed to 1.8 X 10 spores of 
Asperqi11 us fumi gatus. 
Percentage of survival 
Days after therapy 
Formulation I III V VII 
tested 
Untreated 100 40 0 0 
ani mals 
Empty 100 40 
1iposomes 
o 
Free Amp-B 93 40 27 13 
EPC liposomal 100 100 70 60 
Amp-E-i 
EPC/Choi (7:3) 100 80 70 70 
The CHI-square test reveals that the sets of 5 ratios are 
heterogeneous. Comparison of sets showed the significant 
difference between the pairs. 
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Table-Ill 
The in-Fluence of single dose (0.25 mg/kg) of iv. injected 
free or liposomes intercalated amphotericin-B on survival of 
7 
BALE-t/c mice intrave?nously exposed to 18 X 10 spores of 
Asperqi11 us fumiqatus. 
Percent of survival* 
Formulation 
tested 
7 Days after therapy 
Untreated 
animals 
Empty 1 i posomei; 
Fr6?e Amp~B 
EPC liposomal Amp-B 
EPC/Chol (7;3) 45 
The CHI-square test reveals that the sets of three ratios are 
heterogeneous and comparison between the paired of sets 
showed CHI-square test insignificant. 
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Table-IV 
Colony forming units (CFU) o-f Aspergillus -fumigatus in lung 
of infected BALB/c mice on various days after therapy with 
tree and liposomal Amp-B (dose 0.5 mg/kg). 
Formulati on 
tested 
Colony -forming units 
Days after therapy 
III V VII 
Untreated 
animals 
8018 8683 
Empty liposome 8018 8683 
Free Amp--B 3162 1937 2400 3700 
EPC liposomal 
Amp-B 
2500 1875 1250 C>J:L%. 
EPC/Chol (7:3) 187J 1250 0 (J 
The F-test reveals that the difference bejtween the treatment 
of means are heterogeneous and comparison between paired sets 
were analysed and their t values were found to be 
signi fi cant. 
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Table-V 
Colony forming units (CFU) of Asperqi11 us furnigatus in lungs 
of ivifected mice after i.v. injection of free or liposome 
inteeroalateci amphotericin-B. (dose 0.25 mg/kg ). 
Formulation 
testejcl 
Colony forming units 
7 days after therapy 
Untreated 
animals 
None survived 
Empty liposomes None survived 
Free Amp-B 
EF'C liposomal Amp~B 3087 
EPC/Chol (7s3) 
The F~test reveals that the difference between the treatment 
of means sre heterogeneous and comparison between paired of 
sets were analysed and their t values were found to be 
signi f icant-
Table-VI 
Organ concentration of Amp-B (ug/g tissue) following 
intravenous injection of free and liposomal Amp-~Ei in normal 
mice. 
Liposome Lung Liver Spleen Kidney 
Ih 24h Ih 24h Ih 24h Ih 24h 
Free Amp-B 12.6 6.3 44,1 IS.2 36.7 4.2 12.5 5.6 
EPC 3.6 0.9 27.9 15.7 4.8 2.6 5.9 11. El 
EF-'C/Chol 114.5 37.0 54.0 79.1 29.6 53.5 3.8 8.7 
(7:3) 
Mice were injected with either 1 mg/kg free Amp B or <EPC 3.7 
mg/kg, EF="C/Chol 5 mg/kg) liposomal Amp-B intravenously after 
1 hr and 24 hr of injection, the animals were sacrificed and 
various organs such as lung, liver, spleen and kidney were 
taken out processed and subjected to HPLC analysis for Amp-B. 
In all cases the dose was adjusted to 6 mg/kg body weight for 
calculation purposes. Values Are mean of tissue samples (in 
duplicate) obtained from pooled orgcins of six mice each. 
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Table-VII 
Organ concentration of Amp-B <ug/g tissue) -following 
intravenous injection o-f free and liposomal Amp--B in infected 
mi ce. 
Liposome Lung Liver Spleen Kidney 
Ih 24h Ih 24h Ih 24h Ih 24h 
Free Amp-B 21.1 4.6 44.0 14.2 17,7 7.3 26.4 Zl 
EPC 31.1 1.2 19,2 20,1 18.6 6,6 4,8 3.6 
EPC/Chol 131.8 40.8 58.0 53.2 34.6 14,7 9.4 8.6 
(7:3) 
In this case, the doses and other experimental protocol were 
same as given in Table-VI. 
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Table- VIII 
Relative concentration of Amp-B (ug/gm tissue) in different 
organs following intravenous administration of free and 
liposome intercalated Amp-B in Injected and Normal mice. 
Formulation 
(Infected/ Lung Liver Spleen Kidney 
Normal) Ihr 24h Ihr 24hr Ihr 24hr Ihr 24hr 
Free Amp-B 1,67 0.73 0.99 0.78 0.4S 1.74 2.1 6. 
EPC 8.6 1.3 0.69 1. 
EF'C/Chol 1.2 1.1 1,1 0,67 1.2 0.27 2,5 0,98 
(7:3) 
In this case, the dos6?s and other experimental protocol were 
same as given in Texble VI and VII. 
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111,5. EFFECT OF CHOLESTEROL AND SURFACE CHARGE ON LIPOSOMES 
INTERCALATED Amp-B IN THE TREATMENT OF ASPERGILLOSIS AND ITS 
TISSUE DISTRIBUTION IN NORMAL AND INFECTED MICE . 
111.5.1. Survival of animals and colony -forming unit : 
Various formulations of liposome incorporated Amp-B 
with or without cholesterol were prepared. The survival 
pattern of animaus on various days (upto 7 days) after 
therapy is given in Table-IX. It was observed that there 
was no difference in survival of mice after therapy with all 
formulation of liposomes intercalated Amp-B used. 
The fungal count i.n lung after therapy with all types of 
liposomal Amp-Ei reduced remarkably Table-X. In the previous 
section (III.4.1) it was seen that the CPU with neutral EF'C 
liposomes was 625 but when cholesterol was includ6?d in the 
same formulation, the fungal count was nil, showing the 
dramatic effect of cholesterol in re^ducing the fungal count 
upon inclusion of cholesterol in case of neutral liposomes. 
In order to evaluate the role of surface charge and effect of 
cholesterol various kinds of liposomal formulations of Amp-B 
were prepared, which are given as follows: 
Li posomes 
EPC : SA 
EPC : SA : Choi 
EPC : PS 
EPC s PS : CHOL 
Molar Lipid Composition 
7 : 1 
4 : 1 : 3 
9 : 1 
6 : 1 s 3 
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In case of positively charged liposomes with cholesterol 
<EPC: SA: Choi), we found that the fungal count was zero on 
5th day but without cholesterol the fungal count was 625, on 
7th day CFU was zero in both the cases. The therapy with 
Amp-B intercalated into EPC/PS liposomes reduced the CFU to 
50 on 5th day after therapy whereas the CFU value on the same 
day was zero when Amp-B in EF'C/PS/CHOL was used as a 
therapeutic measure-
111.5.2. Positively charged (EPC:SA::7:1) liposomal Amp-B. 
The tissue distribution profiles in normal and 
infected mice after intravenous administration of EPC/SA 
liposomal Amp-B are given in Tables-XI and XII. In lungs, the 
organ concentration of liposomal Amp-B (EPC/SA) in infected 
animals was found to be 2.6 fold higher as compared to normal 
animals but the drug was not detectable in infected animals 
aftfsr 24hr of administration. The initial concesntration of 
EF-'C/EJA liposomaxl Amp~B in liver was 1.4 times higher in 
infected animals as compi^red to normal animals whereas the? 
concentration of Amp-B in infected animals decreases by 1.6 
fold as compared to normal animals. In case of spleen, the 
concentration of Amp-B in spleen of normal animals was 4 
times less to that of infected animals. The concentration of 
drug in spleen after 24hr was 3.8 fold higher in infected 
anima\ls as compared to normaU animals. 
In kidney, the initial concentration of drug was 7.7 
times higher in infected animals to that of normal animals 
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but after 24hr the concentration of drug was not detectable 
in infected mice. 
111.5.3. Amp-B intercalated in (EPC/SA/Chol::4:1:3) liposomes 
The tissue distribution pattern of EPC/SA/Chol 
liposomal Amp-B are given in Tables-XI and XII. In lung after 
Ihr, the concentration of EPC/SA/Chol liposomal Amp-B in 
infected mice was 1.4 fold higher as compared to normal 
animals, whereas the concentration of Amp-B after 24hr was 
found to be 1.3 times higher in infected animals to that of 
normal animals- The liver concentration of EPC/SA/Chol 
liposomal Amp-B after Ihr and 24hr of intravenous 
administration in infecte^d and normal mice was comparable. 
The organ concentration of Amp-B in spleen of infected 
animals after Ihr was comparable to normal animals but 
after 24hr concentration of Amp-B decreases by 1.7 fold in 
infected animals to that of normal animals. In kidney, the 
initial concentration of Amp-B was 1.4 fold higher in 
infected animals as compared to normal animals but after 24hr 
the concentration of the drug was comparable to that of 
normal animals. 
111.5.4. Amp-B intercalated in EPC/PS liposomes 
The organ cocentrations of Amp-B in normal and infected 
mice after intravenous administration of liposomal Amp-B are 
given in Tables-XI and XII. 
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In case of lung, the organ concentrati can of negatively 
charged liposomal (EPC/PS) Amp-B in infected animals was 2,, 3 
•fold higher as compared to normal animals after Ihr of 
intravenous administration of negatively charged liposomal 
Amp B but the concentration of Amp-B after 24hr was not 
detectable in normal mice. The liver concentration of Amp-B 
after Ihr in infected animals was found to be 2.1 fold 
higher whereas after 24hr the concentration of Amp--B was 1.9 
fold higher ^^ B compared to normal animals. 
In spleen, the initial concentration of Amp~B in 
infected animals was 6-8 fold higher as compared to normal 
animals but after 24hr the concentration of Amp--B was 2.9 
fold increased in infected animals to that of normal animals. 
The initial concentration of Amp-B in kidney was not 
detectable in both normal and infected mice .After 24hr the 
concentration of Amp-B was not detectable in infected mice 
but in normal mice the concentration of Amp-B was found tcj be 
6.8 ug/gm of tissue. 
III.5.5. Amp-B intercalated in (EPC/PS/Chol) liposomes 
The tissue distribution patterns after inclusion of 
Cholesterol in positvely charged liposomes intercalated Amp-B 
in normal and infected mice are given in Table-XI and XII. 
The lung concentration of Amp-B after Ihr of 
liposomal Amp-B inJE^ction in infe^cted mice was 1.1 fold 
higher as compared to normal mice but after 24 hr the 
concentration of Amp-B was 1.3 fold higher in infected 
an i mails. 
In liver, the initial concentration of liposomal Amp-B 
in infected animals had decreased tay 1.6 fold as compared to 
normal animals whereas after 24 hr the concentration of Amp-B 
infected animals had decreased by 1.3 fold to that of normal 
ani mals. 
In the case of spleen, the initial concentration of 
Amp-B in infected animals decreased tay 1.7 fold whereas after 
24 hr there was a further decrease of 1.6 fold as compared to 
normal animals. 
The kidney concentration of Amp-B after 1 hr of 
liposomal Amp-B injection was 1.1 fold less in infected 
animals as compared to normal animals. Whereas after 24 hr 
the concentration of Amp-B increased by 1„3 fold in infected 
animals to that of normal animals. 
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Table-IX 
The percentage of survival of animal's on various days after-
therapy with liposome intercalated Amp~B (dose 0,5 mg/kg body 
wt) . 
Liposome Survival of animals on days after therapy 
I III V VII 
EPC/SA <7:1) 100 100 70 70 
EPC/C-3A/Chol 100 32 70 70 
(4:1:3) 
EPC/PS (9:1) 100 90 80 70 
EPC/PS/Chol 100 100 90 80 
(6:1:3) 
The CHI-square test reveals that the sets of 4 ratios are 
hetrogeneous. Comparison of sets showed the insignificant 
difference between the pairs. 
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Table-X 
Colony forming units (CFU) of Aspergillus -fumigatus in lungs 
of infected mice on various days after intravenous injection 
of 0«5 mg/kg of liposomal Amp-B. 
Liposomes CFU on days after therapy 
I III V VII 
EPC/SA 1875 1250 
(7: 1) 
EPC/SA/Chol 2656 1250 0 0 
(4:1:3) 
EPC/PS 1250 625 50 0 
<9s 1) 
EPC/PS/Chol 1250 50 0 0 
< 6: 1:3) 
Since CFU was nil for all treatment except EPC/SA no 
statistical analysis was performed. 
Table-XI 
Organ concentration of Amp-B (ug/g tissue) +ollowing 
intravesnous injection of liposomal Amp-B in normal mice. 
Lipjosome Lung Liver Spleen Kidney 
Ih 24h Ih 24h Ih 24h Ih 24h 
Ef='C/SA 21.1 5.6 29.0 27.8 19.2 7,3 2.8 3.9 
<7s 1) 
EPC/SA/Chol 41.7 9.9 46.3 40.S 24.8 26.7 6.5 6.6 
(4s1:3) 
EPC/PS 8.9 ND 10.2 12.9 4.5 6.1 ND 6.8 
(9: 1) 
EPC/PS/Chol SO.6 29.2 52.4 61.2 71.8 68.2 13.9 6.5 
(6s Is 3) 
The doses of Amp-B in various liposomes were: EF'C/SA 5 mg/kg 
EPC/SA/Chol 6 mg/kg, EPC/PS 5 mg/kg, EPC/PS/Chol 4.3 mg/kg. 
After 1 hr and 24 hr of injection,the animals were sacrificed 
and various organs such as lung, live?r spleen and kidney were 
taken out, processed and subjected to HPLC analysis for 
Amp-B„ In all cases the dose was adjusted to 6 mg/kg body 
weight for calculation purposes. Values iKre mean of tissue 
samples (in duplicate) obtained from pooled organs of si;-; 
mice each. 
NDs Nv3t detectable. 
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Table-XII 
Organ concentration of Amp-B (ug/g tissue) followinq 
intravenous injejction of liposomal Amp-B in infected mice. 
Li posome Lung 
Ih 24h 
Liver 
Ih 24h 
Spleen 
Ih 24h 
Kidney 
Ih 24h 
EPC/SA 
< 7: 1) 
5.3 ND 41.5 16.9 78.6 28.2 21.7 ND 
EPC/SA/Choi 59.5 13,4 45.6 44,8 21.0 15.5 
(4:l5 3) 
8.8 6. 
EPC/PS 
(9: 1) 
20.4 17.1 38.2 24.6 30.6 19.2 ND ND 
EPC/PS/Chol 92.5 38.7 
(6:1:3)3 
48. 42.7 43.2 16.4 3. 
In this case, the doses and other experimental protocol were 
same as given in legands to Table~XI except the dose of 
Amp-B both in EPC/SA and EPC/PS was 1 mg/kg. 
ND: No detectable. 
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Table-XIII 
Relative concentration o-f Amp-B (ug/gm tissue) in di-f •fe?rent 
organs -following intravenous administration ot liposome Amp--B 
in Injected and Normal mice. 
Formulation 
(Infected/ Lung Liver Spleen Kidney 
Normal) Ihr 24h Ihr 24hr Ihr 24hr Ihr 24hr 
EPC/SA 2.6 - 1.4 0.6 4,0 3.8 7,7 
(7:1) 
EPC/SA/Chol 1.4 1,35 0.98 1.1 0.85 0.58 1.35 
(4:1:3) 
EPC/PS 2.3 -- 0.21 1.9 6,8 
(9: 1) 
EPC/PS/Chol 1.2 1.3 0.62 0.79 0.60 0.63 1,2 1 
(6!1:3) 
In this case, the doses and other e;; peri mental protocol were 
same as given in legends to Table XI andXII. 
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111.6 EFFECT OF SURFACE MANNOSE AND CHOLESTEROL IN VARIOUS 
LIPOSOMAL COMPOSITIONS ON IN VIVO THERAPEUTIC EFFICACY AND 
TISSUE DISTRIBUTION OF Amp-B. 
111. 6.1. Treatment o-f infected mice 
To evaluate the ef-fect o-f surfaice mannose and incluBion 
of cholesterol into mannosylated liposomeB, different types 
of liposomal formulations of Amp--B were prepared which are 
given as follows: 
Liposomes 
EPCsChol:DPPE 
EPCsCholsDPPE-Man 
EPC:DPPE-Man 
Molar lipid composition 
6: 1:3 
9: 1 
The survival pattern of animals on various days (upta 7 
days) after therapy with above liposomal formulations of 
Amp-B (0.5 mg/kg) is given in Table~XIV. The animals treated 
with either (EPC/DPPE/Chol) or EPC/DPPE (Mannosylated) 
liposomal formulation of Amp-B led to a significant increase? 
in survival <70X surviving 7 days after therapy), whereas 
inclusion of cholesterol in mannose grafted liposomes showed 
further improvement in survival <1007. surviving 7 days after 
therapy), as compared to untreated animals (none survived 
after 4 days of infection). The fungal count in lung was 
also rceduced remarkably after treatment with the above 
formulations of liposomal Amp-B Table-XI. The fungal count 
in case of mice receiving 0.5 mg/kg liposomal Amp-B 
(EPC/DPF-'E-Man) was 3750 which was reduced to 1562 in mice 
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treated with EPC/Chol/DPPE liposomaa Amp-B aiter 24 hr of 
therapy. In case of animals treated with EPC/Chol/DPPEI-Man 
liposomal -formulation of Amp-B, there was a further decrease 
in fungal load to 1025 which was observed after 24 hr of 
therapy. 
The fungal load in the lung of experimental animals 
treated with either EPC/DPPE-man or EPC/Chol/DPF'E liposomal 
formulation of Amp-B were comparable on 5th day after 
therapy. Animals treated with either EPC/DF"'f--'E~Han or 
or EPC/Chol/DF-'PE; liposomal formulation of Amp-Ei reduced the 
CPU value to 65 and 28 respectively after 7 days of therapy. 
The better therapy in terms of reduction of fungal count 
<2ero) was achieved with Amp-B intercalated into 
EPC/Chol /DF-'PEi;~Man 1 i posomes. 
111.2. Amp-B intercalated in EPC/DPPE-Man liposomes. 
The concentrations of Amp-B in various organs aftcer 
intravenous administration of liposomal Amp-B (EPC/DF'PE-
Mannosylated) arts given in Tables-XVI and XVII, It has been 
observed that the initial lung concentration of Amp-B was 1,6 
fold higher in infected animals as compared to normal animals 
but after 24 hr the concentration of Amp-B was comparable. 
In case of liver, a 3.1 fold increase in concentration of 
Amp-B was noticed in normal animal as compared to infected 
animals taut after 24 hr only l.S fold increase in 
concentration of Amp-B was observed. In spleen, the initial 
concentration of Amp-B was 7.7 fold higher in normal animals 
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as compared to infected animals, whereas after 24 hr 1.4 fold 
increase of concentration of Amp~Ei was noticed in infected 
animals. The kidney concentration of Amp-B was 1.2 fold 
higher in infected animals as compared to normal animals but 
after 24 hr, 1.3 fold increase of concentration of Amp~B was 
noticed in infected animals. 
111.6.3. Amp-B in non-mannosylated (EPC/DPPE/Chol) liposomes. 
The organ concentrations of Amp--B in normal and inftected 
mice after intravenous administration of liposomal Amp-B(EPC/ 
DPPE/Chol) Bre shown in Table-XVI and XVII. The liposomal 
Amp-B increased the lung concentration of infected animals by 
2.4 fold as compared to normal animals after 1 hr of 
administration. In liver, the initial concentration of 
liposomal Amp-B was comparable in infected and normal animals 
but after 24 hr the concentration of drug decreased by 1.2 
fold in infected animals as compared to normal mice. The 
concentration of liposomal Amp-B in spleen after 1 hr was 1,2 
fold decreased in infected animals but afte?r 24 hr the 
concentration of Amp-B was 2.5 fold higher in normal animals. 
In kidney a 1.8 fold decrease in concentration of drug was 
notic€?d in infected animals after 1 hr and 24 hr of drug 
admi n i strat i on. 
111.6.4. Amp-B in EPC/Chol/DPPE-Man liposomes. 
The organ concentration profiles of liposomal Amp-B m 
normal and infected mice after intravenous administration of 
liposomal Amp-B sre given in Tables-XVI and XVII. In lungs, 
31 
the initiail concentration of Amp-B in infected mice was 1.4 
time-'S higher than that in normal animals. After 24 hr the 
Amp-B in lungs of infected animals become 62 fold higher as 
compared to normal animals. In case of liver,the 
concentration of Amp-B in infected animals was 2.4 times less 
as compared to normal animals taut after 24 hr the drug 
concentration was 2.3 fold decreased in infected animails as 
compared to normal animals. In spleen, the initial 
concentration of Amp-B in infected mice was 5.6 times 
decreissed to that in normal mice taut, after 24 hr, 4.7 fold 
decreased concentration of Amp-£ii in infected animals was 
observed. The initial kidney concentration of Amp-B in 
infejcted mice was 1.3 fold less as; compared tcj normal animals 
but after 24 hr, the concentration of drug was 3.£) fold 
higher in infected animals to that in normal animals. 
III.6.5. Tissue distribution of Amp-B intercalated into 
mannose grafted liposomes : Mannan inhibition studies. 
The effect of prior injection of mannan in alttering the 
organ concentration of Amp-B intercalated into mannose 
grafted liposomess is pre?sented in Table-XVll. Remarkable 
difference in the organ concent; ation of Amp-B was observed, 
whe?n mannan was ir.jected 5 min prior to injection of mannose 
grafted lipc,somal Amp-B„ In lungs, the concentration of Amp-
B was 3.2 fold decreased when mannan was injected followed by 
injection of mannosylated liposomal Amp-B in normal animals 
but in case of liver a further decrease of 6.7 fold in 
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concentration o-f Amp~B wais observed as compared to mannan 
untreated animals in normal condition. In spleen, the 
concentration o-f Amp-B was 14 times le?ss, when normal animals 
were treated with mannan followed by mannose grafted 
liposomal Amp-B. Whereas in cases of kidney, the-? 
conce?ntrati on of Amp--B was comparable. In case of infected 
animals the effect of mannan in reducing the concentration of 
mannosylated liposomal Amp-E-i was not so pronounced in liver 
and lung but the effect of mannan was noticed in spleen. In 
case of spleen, the concentration of Amp-B decreased by 1,, 6 
fold as compared to mannan untreated animals. 
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Table-XIV 
The percentctge of survival of animals on various days after 
therapy with liposome intercalated Amp-B (dose 0»5 mg/kg body 
wt) . 
Liposome Survival of animals on days after therapy 
I III V VII 
EPC/Chol/DPPE 100 85 75 70 
(6:3s1) 
EPC/Chol/DPPF£-"Man 100 100 100 100 
(6s3:1) 
EPC/DPPE-Man 100 SO 70 70 
(9: 1) 
Man; Mannose grafted liposome 
CHI-square test did not reveal any heterogenity between the 
survival rate?s hence paired compariscin were not made. 
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Table-XV 
Colony forming units (CFU> oi Asperqi litis -fumiqatus in lungs 
of in + ected mice on varidus days after intravenous injecticsn 
of 0,5 mg/kg of liposomal Amp~B. 
Liposome CFU on days after therapy 
I III V VI1 
EF'C/Chol/DPPE 1562 770 675 28 
(6:3:1) 
EF'C/Chol/DPPE--Man 1025 150 0 0 
(6:3:1) 
EPC/DPPE-Man 
(9: 1) 
Man: Mannose grafted liposome 
The F~t£5st reveals that the difference between the treatment 
of means are heterogeneous and comparison between paired sets 
were analysed and their t values were found to be 
significant. 
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Table-XVI 
Organ concentration o-f Amp-B <ug/g tissue) following 
intravenous injection of liposomal Amp-B in normal mice. 
Liposome Lung Liver Spleen Kidney 
Ih 24h Ih 24h ih 24h Ih 24h 
EPC/Chol/DPPE 31„4 6.6 25.3 47.4 33.9 49.7 9.6 3.8 
(6:3:1) 
EPC/Chol/ 
DPPE-Man 
(6:3:1) 
EPC/DPPE-Man 7.9 31.2 63.5 176,2 84.1 8.2 9.4 12 
<9: 1) 
The^ doses o-f Amp~B in various liposomal groups were?: 
EPC/DPPE--Man (9:1), EPC/Chol/DPPE-Man (6:3:1), 1.75 and 2.14 
mg/kg respectively. In all cases dose has been adjusted to 6 
mg/kg -for calculation purposes. Values are mean of duplicate 
tissue sample obtained from pooled organs of 6 mice each,, 
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Table-XVII 
Organ concentration of Amp-B <ug/g tissue) -following 
intravenous injection o-f liposomal Amp~B in infected mice. 
Liposome Lung Liver Spleen Kidney 
Ih 24h Ih 24h Ih 24h Ih 24h 
(6s3s1) 
EPC/Chol/ 50.4 226.5 45.9 52.4 7.9 11.2 8.4 7.6 
DPPE-lian 
(6:3s1) 
EPC/DPPE-Man 13.4 32.3 20.3 97.8 10,9 11.7 11.3 9.34 
(9: 1) 
The doses of Amp-B in various liposomal groups were: 
EPC/DPPE--Man (9:1), EPC/Chol/DPPE-Man (6:3:1), 1.75 and 2.14 
mg/kg respectively. In all cases dose has been adjusted to 6 
mg/kg for calculation purposes. Values ar-B mean of duplicate 
tissue sample obtained from pooled organs of 6 mice each. 
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Table-XVIII 
Mannan- inhibition study : after 15 min.injection of mannose 
grafted 1 i pcasomal-Amp-B in infected and normal mice. 
Ti sBuee Organ conce?ntration of Amp~B 
(ug Amp-B/g tissue) 
Normal 
-Man H+L-Man 
Infected 
L-Han M+L-Man 
_.unq 4.9 1,5 12.2 13.7 
Li ver 43.9 36. 33.9 
Sp1een 
Kidney 
'•.•"=; 4 
2. 1 
1,8 
1.8 
21,8 
2. 4 
13.6 
Liposome = EPCs Choi : DF='PE-Man (6:3:1) 
Drug injected " 5 mg/kg body wt. of mice. 
Mannan injected (M) = 80 mg/kg body wt. of mice. 
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Table-XIX 
Relative concentration of Amp-B (ug/gm tissue) in different 
organs following intravenous administration of liposome Amp-B 
in Infected and Normal mice. 
Formulation 
(Infected/ Lung Liver Spleen Kidney 
Normal) Ihr 24h Ihr 24hr Ihr 24hr Ihr 24hr 
EPC/Chol/PE 2-4 3.3 0.94 0.79 0.8 0.39 0.55 0.56 
(6:3s1) 
EPC/Chol/ 1.39 62.9 0.41 0.42 0.17 0.21 0.75 3.8 
PE-Man 
(6:3:1) 
EPC/PE-Man 1.7 1.0 0.32 0.55 0.13 1.43 1.2 0.77 
<9: 1) 
In this case, the doses and other experimental protocol were 
same as given in Tables XVI and XVII. 
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CHAPTER 4 
DISCUSSIONS 
DISCUSSION: 
Aspergillosis, a systemic -fungal disease has emerged 
as a life threatening infection specially in immunosupressed 
patients (128--129). Use of immunosupressive drugs during 
transplantation and treatment of several diseases with broad 
spectrum antibiotics are the major causes for 
immunosuppression <130,,4). Amphoteri cin--B as discussed 
earlier although used widely could not serve the purpose of 
an ideal drug as it has several toxic effects (131,132),, 
Continuous efforts are still in progress to se>arch for an 
alternative drug carrier to circumvent this toxicity. As 
m&^ntioned earlier, the present investigation attempts to 
establish liposome as a carrier for Amp--B which could reduce 
toxicity and improve therapeutic efficacy. 
In establishing so, we have developed a mouse model for 
aspergillosis. It is important to mention here that when we 
started our investigation , the animal model system which was 
in wide use was the development of aspergillosis by "Forcing 
animals to inhale fungal spores" using a special type of 
inhaling chamber <133). The major drawback of this model 
system was that although the approach utilises the natural 
way of entry of fungal spores but the number of fungal spores 
inhaled varies from animal to animal and thus it may be 
difficult,to achieve homogeneous infection. The present model 
of aspergillosis described here utilises the intravenous 
injection of fungal sport? with the advantage of getting 
controlled fungal load in the diseased organ-
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Around the time we reported our model on 
aspergillosis, Patterson''s group (134) also described the 
development of aspergillus model in rabbits. The di-f-ference 
in our model and that of F'atterson's group was that they used 
cyclophosphamide before inoculation with aspergillus spores 
but we used only fungal spore. As cyclophosphamide suppresses 
the immune system, the animals become infected with a less 
number of spores as described by Patterson et.al. On the 
contrary in our case as the animals were not immunosupressed, 
we had to use quite a large number of spores as compared to 
that of Patterson et.al. (134), even though the animals used 
by us (mice) weigh less as compared to the animals (rabbits) 
used by them. We have demonstrated that liposomal 
incorporation of Amp-B could reduce the toxicity as evident 
from our L.D data. This is in agreement with observations 
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made by several other investigators (118,119,135,136). The 
exact mechanistic basis for this reduced toxicity of 
liposomal Amp-B is not understood yet. Several researchers 
have different opinions in this regard. Some of 
the studies to search for an explanation on reduced toxicity 
are based on ijn_ vi tro results, and one should be very 
cautious to correlate the i_n vi tro results with i_n vi vo 
phenomena. It has been shown by Juliano's group that Amp-B is 
toxic to red blood cells but L-Amp-B is unable to lyse red 
blood cells in. vitro (113). Further studies on reconst i tut x on 
of Amp-B into liposomes composed of lipids isolated from 
RBCs reflects the fact that L-amp B acts at a cellular level. 
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It. is suggested that i ntesrcalati on of Amp-B into liposomes 
alters its interaction with cells which may confer reduced 
tonicity (117). It is possible that liposomes protect Amp-B 
and release the drug slowly thereby reducing the amount of 
drug released from liposome to amounts that may be below the 
threshold concentration needed not to act on RBCs. Some 
researchers have shown that Amp-B in free form supresses the 
immune status of the host by affecting macrophages through 
impairment of function of cytosolic enzymes such as 
transglutaminase etc. <147). 
The other issue regarding the mode of action of Amp-B 
is sterol specificity. Amp~B has a higher affinity for 
ergosterol than cholesterol and that forms the major basis 
for its use in clinical medicine <137). It does not mean that 
in the presence of fungus Amp~B in free form will not lyse 
the RBCs. It may be suggested that in the case of L-Amp--B it 
only kills fungus. This ca.n be explained by the fact that the: 
amount of Amp-B in liposomal form available in circulation 
is in such an amount which is not enough to lyse RBCs but can 
kill fngus. It is also explainable by the fact that lipossomal 
Amp-.B is taken up by macrophages and does not get a chance to 
interact with RBCs. This is also clear from the observation on 
toxicity of mannose grafted liposomes. Macrophages have an 
affinity for mannose and grafting of mannose onto liposomes 
enhances the uptake of liposomes as is clear from our data 
of mannosylated liposomes which m-e less toxic as compared to 
free drug. Szoka et. al. (122) suggested the reduced and 
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selective toxicity o-f L-Amp-B is because o-f selective 
transfer to liposcDmal drug to fungus. Studies based on the 
physicochemical parameters by Bolard et.al. (138) have shown 
that in liposomes the entire amount of Amp--B does not exist 
in bound form. Some amount of drug remains free and that 
free form may be responsible for the killing process. Once 
the unbound Amp-B attaches to sterol of fungus, it shifts the 
drug which is in bound form in liposomes to free form and 
thereby increases the concentration of Amp-B attached to 
fungus and ultimately this might be facilitating the killing 
process. Jenoff et. al. (139) suggested that lipids cannot 
form liposomes with Amp-B rather it leads to association of 
lipid with Amp~B and this complex is responsible for reduced 
toxicity of the drug- In summary it appears that 
intercalation of Amp-B alters its interaction, it protects 
the f^ 'BCs possibly because of its rapid uptake by 
macrophages. The probable involvement of macrophages in the 
upta\ke of liposomsil Amp-B isi also evident, from our tissue 
deposition studies of L-Amp~B. It was observed that in case 
of L-Amp-B major amount of the drug gets deposited in organs 
rich in macrophages such as liver, spleen and lung. The 
deposition of liposomal drug in kidney was almost negligible 
whch probably accounts for reduced nephrotoxicity. F'revious 
report by Joly et.al.(140) also indicated the prevention of 
toxicity of Amp-B on glomerular filtration when it is used in 
liposome intercalated form. We have prepared various 
liposomal formulation such as positively charged £ P C / S H , 
negatively charged EPC/PS and neutral EPC liposomes with and 
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without cholesterol. For the designing of mannose grafted 
lipo5Dm€5S, liposomes composed of EPC/DPPE with and without 
cholesterol was used. Lopez-Berestein's group (118) used 
large MLV comprised of DMPC and DMF'G. As with MLV" s there is 
a possibility of liposomes being channelised to lung. In 
later studies Szoka et•al. <122) used SUV. Keeping this fact 
in our mind, the liposomal preparations of Amp-B which have 
been used throughout the investigation were mostly of SUV. 
Here we mention that whatever be the formulation of 
liposomes, liposomal intercalation of Amp-B reduces the 
toxicity and improves the therapeutic efficacy with a dose of 
0.5 mg/kg body weight. The incorporation of cholesterol into 
mannosylated 'liposomes has a profound effect in the 
eradication of the fungus resulting in a significant 
improvement in the survival of animals. Thus it appears that 
maximum therapeutic efficacy with Amp-B in mannosylated 
liposomes is achieved only when cholesterol is included in 
1 iposomess. 
The comparative studies on toxicity, therapeutic 
efficacy and tissue distribution of various liposomal 
formulation of Amp-B enables us to predict the effect of 
lipid composition and grafting of mannose onto liposome 
surface. A limited number of studies have also been maude 
earlier to elucidate the role of cholesterol in the liposome 
comf.)osi ti on in altE^ring the toxicity and efficacy of the? 
drug. The reports appear to be controversial. The in vitro 
studies 0)ade by Hopfer et, al. (141) suggest that the inclusion 
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p-f choleBterol into MLVs reduces the toxicity o-f Amp-B, 
however the in vivo studies by the same group indicated that 
the inclusion o-f cholesterol has no bene-ficiai effect (1.20). 
Szoka et. al• (122) have shown that Amp-B incorporated into 
st£?rol contatining SUVs were less toxic as compared to non-
sterol liposomes. We reinvestigated this particular issue in 
the light o-f toxicity, tissue distribution and e-fficacy v\iith 
neutral, negative and positively charged liposomes. We found 
that as compared tcj neutral EPC liposomes, the positively, 
and negatively charged liposomes have a higher LD value. 
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This clearly indicates that as long as cholesterol is not 
used in lipcTsomal preparation, charged liposomes showed 
higher LD than their neutral counterparts. The cholesterol 
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inclusion haxs an added advantage as evident from our LD 
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values with EPC and EPC/Choi liposomes. This is in agreement 
with Szoka's obs6?rvation (122). Keeping in mind the fact that 
certain liposcjmes B.re rapidly taken up by the macrophage 
system, we also studied the effect of cholesterol on the 
to>iicity and theretpeutic efficeicy of positively and 
negatively charged liposomes. The toxicity studies suggest 
that the inclusion of cholesterol in the case of both types 
of liposomes has almost no effect and cholesterol does not 
have any significant effect in reducing the fungal count. 
The survival pattern is almost similar in all types of 
liposomes. Inclusion of cholesterol in liposomes alters the 
distribution of Amp--B in various organs both in normal and 
infected mice. In infected mice, it was observed that 
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cholesterol inclusion in EPC and EPC/PS liposomes increased 
the organ concentration of the drug in lung, spleen, and 
liver whereas EPC/SA liposome cholestt^rol did not increase 
the concentration o-f the drug in lung and liver (except after 
24 h o-f injection). There was 3. decrease in drug 
concentration in spleen when cholesterol was included in 
EPC/SA liposomes. In the case of EPC liposomes, the uptake by 
macrophages is not rapid, whereas negatively charged EF'C/PS 
lipcisomes are rapidly taken up by macrophages which could 
explain the different tissue distriiauti on pattern. In all 
cases, liposomal Amp-B had a low concentration in the kidney 
as ccjmpared to the free drug, in contrast to our results 
with free Amp-B» From comparative studies on the tissue 
distribution of Amp~B in EPC and EPC/Chol liposomes, an 
interesting observation has been made. Thus the level of 
Amp-B is not sustained in the lung as there is a dramatic 
drop in the case of infected animals after 24 h. The same is 
true with positively and negatively charged liposome?s without 
cholesterol (146). It is clear from these observations that 
the cholesterol free liposomal preparation is less staible. 
The drug carrying capacity of such liposomes is reduced with 
conse^quent reducticjn in the amciunt of drug delivered to 
target organ e.g. lung. 
Considering the toxicity, efficacy, and tissue 
distribution pattern, we suggest that inclusion of cholesterol 
in neutral EPC liposomes dramatically reduces the toxicity 
and fungal load and increases the organ concentration of 
Amp--B. In case o+ liposomal drug, it has been proposed that. 
liposomal drug is taken up by macrophages and then 
macrophages home the liposomal drug to the infected tissues. 
Earlier we discussed the implication o-f macrophages while 
critically analysing the effect of cholesterol incorporation 
into liposomes on the therapeutic potency. The probable 
involvement of macrophages in the uptake process is quite 
evident from the increased deposition of liposomal Amp-B in 
organs rich in macrophages system. The presence of mannose 
receptors on a variety of macrophages such as peritoneal, 
alveolar and kupffe?r cells is well documented. Considering 
the fact that macrophages take up mannosylated liposomes 
efficiently we studied the effect of cholesterol 
incorporation in manvTosyl ated liposomes in modulating the 
therapeutic efficacy. Our studies indicate that cholesterol 
incorporation into ms^nnose grafted EPC/DPPE-MAiM liposomes 
increased the LD value significantly which indicates that 
50 
the permissible dose? for injection would be the highest in 
case of mannosylated liposomes. In order to investigate the 
possibility the^ t increased deposition of liposomal drug in 
the infected tissues could provide an explanation for an 
increased therapeutic efficacy of liposomal Amp-B, we have 
also studied the tissue distribution of liposomal and free 
Amp-B. We have observed an increase in the concentration of 
Amp-B in lung following administration of Amp-B m free as 
well as in liposomal form in infected animads. 
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Our observations are in agreement with those made by 
previous invejstigators who have also reported the more uptake 
o-f liposomal Amp-B in affected orgatns of infected mice then 
found in normal mice (121). This could be attributed to 
damage in capillaries of various organs. In case of 
mannosylated liposomes, the organ concentration of Amp-B is 
increased markedly both in normal and infected mice as 
compared to non-mannosylated liposomes. To investigate 
whether or not the mannose receptors ars involved in the 
uptake process of lipjosomes, the mannan inhibition study was 
performed. We have observed that in case of normal animals, 
the mannan strongly inhibits the uptake process in normal 
animals, where circulatory monocytes are not activated, the 
mocrophages have a reasonable number of mannose receptors, 
(142-144). Therefore the uptake of liposomes by macrophages 
occurs through reecteptor mediated endocytosis. But in case 
of infected animals, we could not get inhibition in the 
uptcike of mannosylated liposomes tay mannan As reported 
earlier there is a dimunition of mannose receptors in 
activated macrophages (145), it is reasonable to believe that 
circulating macrophages of infected animals do not have 
mannose receptor to achieve the receptor mediated uptake of 
mannose grafted liposomes. Still we could find an increased 
concentration of Amp-E< in tissues of animals which received 
Amp-B intercalated in mannosylated liposomes. Whether the 
other uptake mechanism is involved or the resident 
m£tcrophages have some role to play with uptake process needs 
f ur t h er investigation. 
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SUMMARY 
SUMMARY 
Aspergillosis, an opportunistic systemic fungal 
infection is of major concern in clinical medicine specially 
•for immunocompromised patients. Amp-B, although used widely 
as anti-fungal drug, does not seem to be ideal because of its 
severe toxicity. The present investigation describes the use 
of liposome as drug carrier for Amp-B to circumvent the 
toxicity and also to improve the therapeutic potency in 
experimental animal. 
The first part of the thesis deals with the development 
of animal model for Aspergillosis in BALB/c mice. The 
model has been developed by intravenous challenge of a 
7 
definite number of Aspergillus fumigatus spore (1.8 X 10 ) 
in mice. In this model, the animal developed disseminated 
fungal infection as evident from the presence of fungus in 
lung and they survived for 3--4 days. Thus one can get 
sufficient time to start the therapy for comparative 
evaluation. 
The toxicological studies of free and liposomal Amp-B 
constitute the second part of the thesis. In this part, it 
has been demonstrated that the intercalation of Amp-Ei into 
liposomes irresspect i ve of the lipid composition increases the 
LD vail ue ( approx i mate^l y 7.1 times more). Positively and 
50 
negatively charged liposomes without cholesterol has a higher 
LD than neutral without cholesterol. Incorporation of 
50 
chole?sterol into neutral liposomes increase the LD whereas 
50 
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cholestercDl inclusion has no -further ef-fect in increasing the 
LD o-f charged liposomes. As liposomes are taken up by 
50 
macrophages, the attachment of molecules having affinity for 
macrophages may increase the LD further. This is quite 
50 
evident from our observations which states the fact that 
Amp-"B intercalated into EPC/Chol/DPPE--Man liposomes has a 
LD value 20,3 mg/kg which is the highest among all 
50 
liposomal preparation te^ sted in experimental mice. 
The survival of mice following therapy and the fungal 
load in infected tissue such as lung have been checked to 
study the comparative therapeutic efficacy of free and 
liposome intercalated Amp-B, The dose used for both free and 
liposomal Amp-B was 0.5 mg/kg body wt, The animals which 
were left untreated or treated with empty liposomes did not 
survive after "5 days of infection. The survivail of animals 
after 7 days of therapy with free amp-B was IZX. Liposomstl 
intercalation of Amp-B improved the survival which 
range^ d from 60-:i.00/C. Mannose grafted Amp-B intercalated into 
liposomes when given as therapy, t.he survival after 7 days 
was lOOX, This clearly indicated that the intercalation of 
Amp B into liposomes improves the survival of animal as 
compared to Amp--B. 
The extent of eradication of fungal spore in the lung 
has been determined by colony forming unit <CFIJ) . The value 
of CPU in lung of untreate^d animals after 24 h of spore 
challenge was 8018 which was reduced to 3700 in mice treated 
with free drug after 7 days of therapy. In the case of mice 
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receiving various L-Amp-B •formulation. The CPU in lung 
reduced significantly to values ranging from 625 to 0. 
The role of cholesterol in the liposome composition in 
altering the efficacy of Amp-B has been studied,, As far as 
survival of mice is concerned, cholesterol incorporation has 
no effect. in improving the survival in all types of 
liposomes. The fungal count in lung (CPU) on 7 day after 
therapy with EPC-L-Amp--B was 625 but when cholesterol was 
included the fungal count was nil. In the case of 
EF^C/SA/Chol liposomes, the fungal count was zero on the fifth 
day but without cholesterol (EPC/SA liposome) the fungal 
count was 625. The therapy with Amp-B intercalated into 
EF'C/PS reduced CPU to 50 on the fifth day after therapy 
whereas the CPU was zero when Amp-B incorporated into 
EPC/PS/Chol liposome was used. Cholesterol inclusion in 
mannosylated liposome has also a profound effect in reducir\g 
CFU value. The therapy with Amp-B intercalated into 
mannosylated liposomes without cholesterol reduced CPU to 65, 
whereas cholesterol inclusion liposomes (mannose) reduced CPU 
to 0 after 7 days of therapy. The last part of the thesis 
describes the tissue distribution of Amp-B in free form and 
in liposomal form both in normal and infected mice. This 
refle-?cts to the fact that there is an alteration in the 
tissue distribution pattern of Amp--B intercalated into 
liposomes. It also states the fact that tissue damage may 
lead to change in the tissue distribution both in ca^e of 
free and liposomal drug. Tissue distribution analysis of 
101 
Amp-B by HF'LC showed an increase in concentration of the drug 
in lung -for both free and liposomal Amp-B in infected animals 
as compared to normal. Use of liposomal Amp-B increaised the 
concentration of the drug in the disease affected organs such 
as lung and spleen. A longe^ r persistance of the drug in the 
infected organs was also observed. In infected animals the 
inclusion of cholesterol in EPC and EPC/F'S liposomes 
increased the organ concentration of the drug in lung, E-pleen 
and liver. However cholesterol incorporation in EPC/SA 
liposomes did not increase the drug concentration in lung and 
liver except after 24th of injection. A decrease in Amp B 
concentration in spleen was observed when cholesterol had 
been included in EPC/SA liposomes. The level of Amp-B is not 
sustained in the lung as there is a dramatic drop in the case? 
of infected animals after 24 h. The simili-tr type? of 
observations were made with positively and negatively charged 
1i posomes wi thout cholesterol. 
An increased concentration of Amp-B in various o'-yans 
such as lung, liver, spleen of both normal and infected 
mice was observed, when A.T.p-B was intercalated into 
mannosylated liposor;.es as compared to non-mannosyi ated 
1 ip';r:.,omes. A considerably higher amount of drug is deposited 
in lunc^  of infected animals as compared to normal. Prior 
injection of mannan could block the uptake of mannose grafted 
liposomes in case of normal mice as evident from a decrease 
in organ concentration of Amp-B in various tissues. In case 
of infected animals, although an increased uptake of Amp-B 
102 
was observed by vaxriouB tissues but mannan was unable to 
inhibit the uptake. This could be attributed to the -fact 
that in case of infected animals the receptor for mannose on 
activated macrophages is either diminished or abrogated and 
thus no inhibition was observed taut the mannose receptor 
still may be present on resident tissue macrophages which 
may take part in the uptake process of liposcjmal drug, 
thereby increasing the concentration of Amp--B intercalated 
i nto mannose gr af ted 1i posomes. 
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